1
|
Saracino D, Sellami L, Boniface H, Houot M, Pélégrini-Issac M, Funkiewiez A, Rinaldi D, Locatelli M, Azuar C, Causse-Lemercier V, Jaillard A, Pasquier F, Chastan M, Wallon D, Hitzel A, Pariente J, Pallardy A, Boutoleau-Bretonnière C, Guedj E, Didic M, Migliaccio R, Kas A, Habert MO, Le Ber I. Brain Metabolic Profile in Presymptomatic GRN Carriers Throughout a 5-Year Follow-up. Neurology 2023; 100:e396-e407. [PMID: 36257714 DOI: 10.1212/wnl.0000000000201439] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2022] [Accepted: 09/06/2022] [Indexed: 02/05/2023] Open
Abstract
BACKGROUND AND OBJECTIVES GRN variants are a frequent cause of familial frontotemporal dementia (FTD). Monitoring disease progression in asymptomatic carriers of genetic variants is a major challenge in delivering preventative therapies before clinical onset. This study aimed to assess the usefulness of fluorodeoxyglucose (FDG)-PET in identifying metabolic changes in presymptomatic GRN carriers (PS-GRN+) and to trace their longitudinal progression. METHODS Participants were longitudinally evaluated over 5 years in a prospective cohort study focused on GRN disease (Predict-PGRN). They underwent cognitive/behavioral assessment, plasma neurofilament measurement, brain MRI, and FDG-PET. Voxel-wise comparisons of structural and metabolic imaging data between 2 groups were performed for each time point. Longitudinal PET changes were evaluated with voxel-wise comparisons and the metabolic percent annual changes method. The association of regional brain metabolism with plasma neurofilament and cognitive changes was analyzed. RESULTS Among the 80 individuals enrolled in the study, 58 (27 PS-GRN+ and 31 noncarriers) were included in the analyses. Cross-sectional comparisons between PS-GRN+ and controls found a significant hypometabolism in the left superior temporal sulcus (STS) region (encompassing the middle and superior temporal gyri), approximately 15 years before the expected disease onset, without significant cortical atrophy. The longitudinal metabolic decline over the following 5 years peaked around the right STS in carriers (p < 0.001), without significantly greater volume loss compared with that in controls. Their estimated annualized metabolic decrease (-1.37%) was higher than that in controls (-0.21%, p = 0.004). Lower glucose uptake was associated with higher neurofilament increase (p = 0.003) and lower frontal cognitive scores (p = 0.014) in PS-GRN+. DISCUSSION This study detected brain metabolic changes in the STS region, preceding structural and cognitive alterations, thus contributing to the characterization of the pathochronology of preclinical GRN disease. Owing to the STS involvement in the perception of facially communicated cues, it is likely that its dysfunction contributes to social cognition deficits characterizing FTD. Overall, our study highlights brain metabolic changes as an early disease-tracking biomarker and proposes annualized percent decrease as a metric to monitor therapeutic response in forthcoming trials.
Collapse
Affiliation(s)
- Dario Saracino
- From the Sorbonne Université (D.S., L.S., M.H., A.F., D.R., M.L., R.M., I.L.B.), Paris Brain Institute-Institut du Cerveau-ICM, Inserm U1127, CNRS UMR 7225, Paris, France; IM2A (D.S., M.H., A.F., D.R., C.A., R.M., I.L.B.), Reference Centre for Rare or Early-Onset Dementias, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Aramis Project Team (D.S.), Inria Research Center of Paris, France; Sorbonne Université (H.B., M.P.-I., M.L., A.K., M.-O.H.), CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, LIB, Paris, France; Centre d'Acquisition et de Traitement d'Images (CATI) (H.B., M.L., A.K., M.-O.H.), US52-UAR2031, CEA, ICM, SU, CNRS, INSERM, APHP, Ile de France, France; Université Paris-Saclay (H.B.), CEA, CNRS, Neurospin, UMR9027 Baobab, Gif-sur-Yvette, France; Centre of Excellence of Neurodegenerative Disease (CoEN) (M.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Département de Médecine Nucléaire (V.C.-L., A.K., M.-O.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Nuclear Medicine Department (A.J.), CHU Lille, Lille, France; Univ Lille (F.P.), Inserm U1172, CHU Lille, DistAlz, LiCEND, CNR-MAJ, France; Department of Nuclear Medicine (M.C.), Centre Henri Becquerel, Rouen University Hospital, France; Normandie Univ (D.W.), UNIROUEN, Inserm U1245 and CHU Rouen, Department of Neurology, CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, CIC-CRB1404, Rouen, France; Nuclear Medicine Department (A.H.), Toulouse Purpan University Hospital, France; Department of Neurology and ToNIC (J.P.), Toulouse NeuroImaging Centre, Inserm, UPS, Toulouse University Hospital, France; Nuclear Medicine Department (A.P.), University Hospital of Nantes, France; CHU Nantes (C.B.-B.), Inserm CIC04, Department of Neurology, Centre Mémoire de Ressources et Recherche, Nantes, France; Nuclear Medicine Department (E.G.), Aix-Marseille University, APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, France; APHM (M.D.), Timone, Service de Neurologie et Neuropsychologie, APHM-Hôpital Timone Adultes, Marseille, France; and Aix-Marseille Univ (M.D.), INSERM, INS Institut de Neurosciences des Systèmes, France
| | - Leila Sellami
- From the Sorbonne Université (D.S., L.S., M.H., A.F., D.R., M.L., R.M., I.L.B.), Paris Brain Institute-Institut du Cerveau-ICM, Inserm U1127, CNRS UMR 7225, Paris, France; IM2A (D.S., M.H., A.F., D.R., C.A., R.M., I.L.B.), Reference Centre for Rare or Early-Onset Dementias, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Aramis Project Team (D.S.), Inria Research Center of Paris, France; Sorbonne Université (H.B., M.P.-I., M.L., A.K., M.-O.H.), CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, LIB, Paris, France; Centre d'Acquisition et de Traitement d'Images (CATI) (H.B., M.L., A.K., M.-O.H.), US52-UAR2031, CEA, ICM, SU, CNRS, INSERM, APHP, Ile de France, France; Université Paris-Saclay (H.B.), CEA, CNRS, Neurospin, UMR9027 Baobab, Gif-sur-Yvette, France; Centre of Excellence of Neurodegenerative Disease (CoEN) (M.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Département de Médecine Nucléaire (V.C.-L., A.K., M.-O.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Nuclear Medicine Department (A.J.), CHU Lille, Lille, France; Univ Lille (F.P.), Inserm U1172, CHU Lille, DistAlz, LiCEND, CNR-MAJ, France; Department of Nuclear Medicine (M.C.), Centre Henri Becquerel, Rouen University Hospital, France; Normandie Univ (D.W.), UNIROUEN, Inserm U1245 and CHU Rouen, Department of Neurology, CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, CIC-CRB1404, Rouen, France; Nuclear Medicine Department (A.H.), Toulouse Purpan University Hospital, France; Department of Neurology and ToNIC (J.P.), Toulouse NeuroImaging Centre, Inserm, UPS, Toulouse University Hospital, France; Nuclear Medicine Department (A.P.), University Hospital of Nantes, France; CHU Nantes (C.B.-B.), Inserm CIC04, Department of Neurology, Centre Mémoire de Ressources et Recherche, Nantes, France; Nuclear Medicine Department (E.G.), Aix-Marseille University, APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, France; APHM (M.D.), Timone, Service de Neurologie et Neuropsychologie, APHM-Hôpital Timone Adultes, Marseille, France; and Aix-Marseille Univ (M.D.), INSERM, INS Institut de Neurosciences des Systèmes, France
| | - Hugo Boniface
- From the Sorbonne Université (D.S., L.S., M.H., A.F., D.R., M.L., R.M., I.L.B.), Paris Brain Institute-Institut du Cerveau-ICM, Inserm U1127, CNRS UMR 7225, Paris, France; IM2A (D.S., M.H., A.F., D.R., C.A., R.M., I.L.B.), Reference Centre for Rare or Early-Onset Dementias, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Aramis Project Team (D.S.), Inria Research Center of Paris, France; Sorbonne Université (H.B., M.P.-I., M.L., A.K., M.-O.H.), CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, LIB, Paris, France; Centre d'Acquisition et de Traitement d'Images (CATI) (H.B., M.L., A.K., M.-O.H.), US52-UAR2031, CEA, ICM, SU, CNRS, INSERM, APHP, Ile de France, France; Université Paris-Saclay (H.B.), CEA, CNRS, Neurospin, UMR9027 Baobab, Gif-sur-Yvette, France; Centre of Excellence of Neurodegenerative Disease (CoEN) (M.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Département de Médecine Nucléaire (V.C.-L., A.K., M.-O.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Nuclear Medicine Department (A.J.), CHU Lille, Lille, France; Univ Lille (F.P.), Inserm U1172, CHU Lille, DistAlz, LiCEND, CNR-MAJ, France; Department of Nuclear Medicine (M.C.), Centre Henri Becquerel, Rouen University Hospital, France; Normandie Univ (D.W.), UNIROUEN, Inserm U1245 and CHU Rouen, Department of Neurology, CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, CIC-CRB1404, Rouen, France; Nuclear Medicine Department (A.H.), Toulouse Purpan University Hospital, France; Department of Neurology and ToNIC (J.P.), Toulouse NeuroImaging Centre, Inserm, UPS, Toulouse University Hospital, France; Nuclear Medicine Department (A.P.), University Hospital of Nantes, France; CHU Nantes (C.B.-B.), Inserm CIC04, Department of Neurology, Centre Mémoire de Ressources et Recherche, Nantes, France; Nuclear Medicine Department (E.G.), Aix-Marseille University, APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, France; APHM (M.D.), Timone, Service de Neurologie et Neuropsychologie, APHM-Hôpital Timone Adultes, Marseille, France; and Aix-Marseille Univ (M.D.), INSERM, INS Institut de Neurosciences des Systèmes, France
| | - Marion Houot
- From the Sorbonne Université (D.S., L.S., M.H., A.F., D.R., M.L., R.M., I.L.B.), Paris Brain Institute-Institut du Cerveau-ICM, Inserm U1127, CNRS UMR 7225, Paris, France; IM2A (D.S., M.H., A.F., D.R., C.A., R.M., I.L.B.), Reference Centre for Rare or Early-Onset Dementias, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Aramis Project Team (D.S.), Inria Research Center of Paris, France; Sorbonne Université (H.B., M.P.-I., M.L., A.K., M.-O.H.), CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, LIB, Paris, France; Centre d'Acquisition et de Traitement d'Images (CATI) (H.B., M.L., A.K., M.-O.H.), US52-UAR2031, CEA, ICM, SU, CNRS, INSERM, APHP, Ile de France, France; Université Paris-Saclay (H.B.), CEA, CNRS, Neurospin, UMR9027 Baobab, Gif-sur-Yvette, France; Centre of Excellence of Neurodegenerative Disease (CoEN) (M.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Département de Médecine Nucléaire (V.C.-L., A.K., M.-O.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Nuclear Medicine Department (A.J.), CHU Lille, Lille, France; Univ Lille (F.P.), Inserm U1172, CHU Lille, DistAlz, LiCEND, CNR-MAJ, France; Department of Nuclear Medicine (M.C.), Centre Henri Becquerel, Rouen University Hospital, France; Normandie Univ (D.W.), UNIROUEN, Inserm U1245 and CHU Rouen, Department of Neurology, CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, CIC-CRB1404, Rouen, France; Nuclear Medicine Department (A.H.), Toulouse Purpan University Hospital, France; Department of Neurology and ToNIC (J.P.), Toulouse NeuroImaging Centre, Inserm, UPS, Toulouse University Hospital, France; Nuclear Medicine Department (A.P.), University Hospital of Nantes, France; CHU Nantes (C.B.-B.), Inserm CIC04, Department of Neurology, Centre Mémoire de Ressources et Recherche, Nantes, France; Nuclear Medicine Department (E.G.), Aix-Marseille University, APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, France; APHM (M.D.), Timone, Service de Neurologie et Neuropsychologie, APHM-Hôpital Timone Adultes, Marseille, France; and Aix-Marseille Univ (M.D.), INSERM, INS Institut de Neurosciences des Systèmes, France
| | - Mélanie Pélégrini-Issac
- From the Sorbonne Université (D.S., L.S., M.H., A.F., D.R., M.L., R.M., I.L.B.), Paris Brain Institute-Institut du Cerveau-ICM, Inserm U1127, CNRS UMR 7225, Paris, France; IM2A (D.S., M.H., A.F., D.R., C.A., R.M., I.L.B.), Reference Centre for Rare or Early-Onset Dementias, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Aramis Project Team (D.S.), Inria Research Center of Paris, France; Sorbonne Université (H.B., M.P.-I., M.L., A.K., M.-O.H.), CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, LIB, Paris, France; Centre d'Acquisition et de Traitement d'Images (CATI) (H.B., M.L., A.K., M.-O.H.), US52-UAR2031, CEA, ICM, SU, CNRS, INSERM, APHP, Ile de France, France; Université Paris-Saclay (H.B.), CEA, CNRS, Neurospin, UMR9027 Baobab, Gif-sur-Yvette, France; Centre of Excellence of Neurodegenerative Disease (CoEN) (M.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Département de Médecine Nucléaire (V.C.-L., A.K., M.-O.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Nuclear Medicine Department (A.J.), CHU Lille, Lille, France; Univ Lille (F.P.), Inserm U1172, CHU Lille, DistAlz, LiCEND, CNR-MAJ, France; Department of Nuclear Medicine (M.C.), Centre Henri Becquerel, Rouen University Hospital, France; Normandie Univ (D.W.), UNIROUEN, Inserm U1245 and CHU Rouen, Department of Neurology, CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, CIC-CRB1404, Rouen, France; Nuclear Medicine Department (A.H.), Toulouse Purpan University Hospital, France; Department of Neurology and ToNIC (J.P.), Toulouse NeuroImaging Centre, Inserm, UPS, Toulouse University Hospital, France; Nuclear Medicine Department (A.P.), University Hospital of Nantes, France; CHU Nantes (C.B.-B.), Inserm CIC04, Department of Neurology, Centre Mémoire de Ressources et Recherche, Nantes, France; Nuclear Medicine Department (E.G.), Aix-Marseille University, APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, France; APHM (M.D.), Timone, Service de Neurologie et Neuropsychologie, APHM-Hôpital Timone Adultes, Marseille, France; and Aix-Marseille Univ (M.D.), INSERM, INS Institut de Neurosciences des Systèmes, France
| | - Aurélie Funkiewiez
- From the Sorbonne Université (D.S., L.S., M.H., A.F., D.R., M.L., R.M., I.L.B.), Paris Brain Institute-Institut du Cerveau-ICM, Inserm U1127, CNRS UMR 7225, Paris, France; IM2A (D.S., M.H., A.F., D.R., C.A., R.M., I.L.B.), Reference Centre for Rare or Early-Onset Dementias, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Aramis Project Team (D.S.), Inria Research Center of Paris, France; Sorbonne Université (H.B., M.P.-I., M.L., A.K., M.-O.H.), CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, LIB, Paris, France; Centre d'Acquisition et de Traitement d'Images (CATI) (H.B., M.L., A.K., M.-O.H.), US52-UAR2031, CEA, ICM, SU, CNRS, INSERM, APHP, Ile de France, France; Université Paris-Saclay (H.B.), CEA, CNRS, Neurospin, UMR9027 Baobab, Gif-sur-Yvette, France; Centre of Excellence of Neurodegenerative Disease (CoEN) (M.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Département de Médecine Nucléaire (V.C.-L., A.K., M.-O.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Nuclear Medicine Department (A.J.), CHU Lille, Lille, France; Univ Lille (F.P.), Inserm U1172, CHU Lille, DistAlz, LiCEND, CNR-MAJ, France; Department of Nuclear Medicine (M.C.), Centre Henri Becquerel, Rouen University Hospital, France; Normandie Univ (D.W.), UNIROUEN, Inserm U1245 and CHU Rouen, Department of Neurology, CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, CIC-CRB1404, Rouen, France; Nuclear Medicine Department (A.H.), Toulouse Purpan University Hospital, France; Department of Neurology and ToNIC (J.P.), Toulouse NeuroImaging Centre, Inserm, UPS, Toulouse University Hospital, France; Nuclear Medicine Department (A.P.), University Hospital of Nantes, France; CHU Nantes (C.B.-B.), Inserm CIC04, Department of Neurology, Centre Mémoire de Ressources et Recherche, Nantes, France; Nuclear Medicine Department (E.G.), Aix-Marseille University, APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, France; APHM (M.D.), Timone, Service de Neurologie et Neuropsychologie, APHM-Hôpital Timone Adultes, Marseille, France; and Aix-Marseille Univ (M.D.), INSERM, INS Institut de Neurosciences des Systèmes, France
| | - Daisy Rinaldi
- From the Sorbonne Université (D.S., L.S., M.H., A.F., D.R., M.L., R.M., I.L.B.), Paris Brain Institute-Institut du Cerveau-ICM, Inserm U1127, CNRS UMR 7225, Paris, France; IM2A (D.S., M.H., A.F., D.R., C.A., R.M., I.L.B.), Reference Centre for Rare or Early-Onset Dementias, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Aramis Project Team (D.S.), Inria Research Center of Paris, France; Sorbonne Université (H.B., M.P.-I., M.L., A.K., M.-O.H.), CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, LIB, Paris, France; Centre d'Acquisition et de Traitement d'Images (CATI) (H.B., M.L., A.K., M.-O.H.), US52-UAR2031, CEA, ICM, SU, CNRS, INSERM, APHP, Ile de France, France; Université Paris-Saclay (H.B.), CEA, CNRS, Neurospin, UMR9027 Baobab, Gif-sur-Yvette, France; Centre of Excellence of Neurodegenerative Disease (CoEN) (M.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Département de Médecine Nucléaire (V.C.-L., A.K., M.-O.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Nuclear Medicine Department (A.J.), CHU Lille, Lille, France; Univ Lille (F.P.), Inserm U1172, CHU Lille, DistAlz, LiCEND, CNR-MAJ, France; Department of Nuclear Medicine (M.C.), Centre Henri Becquerel, Rouen University Hospital, France; Normandie Univ (D.W.), UNIROUEN, Inserm U1245 and CHU Rouen, Department of Neurology, CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, CIC-CRB1404, Rouen, France; Nuclear Medicine Department (A.H.), Toulouse Purpan University Hospital, France; Department of Neurology and ToNIC (J.P.), Toulouse NeuroImaging Centre, Inserm, UPS, Toulouse University Hospital, France; Nuclear Medicine Department (A.P.), University Hospital of Nantes, France; CHU Nantes (C.B.-B.), Inserm CIC04, Department of Neurology, Centre Mémoire de Ressources et Recherche, Nantes, France; Nuclear Medicine Department (E.G.), Aix-Marseille University, APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, France; APHM (M.D.), Timone, Service de Neurologie et Neuropsychologie, APHM-Hôpital Timone Adultes, Marseille, France; and Aix-Marseille Univ (M.D.), INSERM, INS Institut de Neurosciences des Systèmes, France
| | - Maxime Locatelli
- From the Sorbonne Université (D.S., L.S., M.H., A.F., D.R., M.L., R.M., I.L.B.), Paris Brain Institute-Institut du Cerveau-ICM, Inserm U1127, CNRS UMR 7225, Paris, France; IM2A (D.S., M.H., A.F., D.R., C.A., R.M., I.L.B.), Reference Centre for Rare or Early-Onset Dementias, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Aramis Project Team (D.S.), Inria Research Center of Paris, France; Sorbonne Université (H.B., M.P.-I., M.L., A.K., M.-O.H.), CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, LIB, Paris, France; Centre d'Acquisition et de Traitement d'Images (CATI) (H.B., M.L., A.K., M.-O.H.), US52-UAR2031, CEA, ICM, SU, CNRS, INSERM, APHP, Ile de France, France; Université Paris-Saclay (H.B.), CEA, CNRS, Neurospin, UMR9027 Baobab, Gif-sur-Yvette, France; Centre of Excellence of Neurodegenerative Disease (CoEN) (M.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Département de Médecine Nucléaire (V.C.-L., A.K., M.-O.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Nuclear Medicine Department (A.J.), CHU Lille, Lille, France; Univ Lille (F.P.), Inserm U1172, CHU Lille, DistAlz, LiCEND, CNR-MAJ, France; Department of Nuclear Medicine (M.C.), Centre Henri Becquerel, Rouen University Hospital, France; Normandie Univ (D.W.), UNIROUEN, Inserm U1245 and CHU Rouen, Department of Neurology, CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, CIC-CRB1404, Rouen, France; Nuclear Medicine Department (A.H.), Toulouse Purpan University Hospital, France; Department of Neurology and ToNIC (J.P.), Toulouse NeuroImaging Centre, Inserm, UPS, Toulouse University Hospital, France; Nuclear Medicine Department (A.P.), University Hospital of Nantes, France; CHU Nantes (C.B.-B.), Inserm CIC04, Department of Neurology, Centre Mémoire de Ressources et Recherche, Nantes, France; Nuclear Medicine Department (E.G.), Aix-Marseille University, APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, France; APHM (M.D.), Timone, Service de Neurologie et Neuropsychologie, APHM-Hôpital Timone Adultes, Marseille, France; and Aix-Marseille Univ (M.D.), INSERM, INS Institut de Neurosciences des Systèmes, France
| | - Carole Azuar
- From the Sorbonne Université (D.S., L.S., M.H., A.F., D.R., M.L., R.M., I.L.B.), Paris Brain Institute-Institut du Cerveau-ICM, Inserm U1127, CNRS UMR 7225, Paris, France; IM2A (D.S., M.H., A.F., D.R., C.A., R.M., I.L.B.), Reference Centre for Rare or Early-Onset Dementias, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Aramis Project Team (D.S.), Inria Research Center of Paris, France; Sorbonne Université (H.B., M.P.-I., M.L., A.K., M.-O.H.), CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, LIB, Paris, France; Centre d'Acquisition et de Traitement d'Images (CATI) (H.B., M.L., A.K., M.-O.H.), US52-UAR2031, CEA, ICM, SU, CNRS, INSERM, APHP, Ile de France, France; Université Paris-Saclay (H.B.), CEA, CNRS, Neurospin, UMR9027 Baobab, Gif-sur-Yvette, France; Centre of Excellence of Neurodegenerative Disease (CoEN) (M.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Département de Médecine Nucléaire (V.C.-L., A.K., M.-O.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Nuclear Medicine Department (A.J.), CHU Lille, Lille, France; Univ Lille (F.P.), Inserm U1172, CHU Lille, DistAlz, LiCEND, CNR-MAJ, France; Department of Nuclear Medicine (M.C.), Centre Henri Becquerel, Rouen University Hospital, France; Normandie Univ (D.W.), UNIROUEN, Inserm U1245 and CHU Rouen, Department of Neurology, CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, CIC-CRB1404, Rouen, France; Nuclear Medicine Department (A.H.), Toulouse Purpan University Hospital, France; Department of Neurology and ToNIC (J.P.), Toulouse NeuroImaging Centre, Inserm, UPS, Toulouse University Hospital, France; Nuclear Medicine Department (A.P.), University Hospital of Nantes, France; CHU Nantes (C.B.-B.), Inserm CIC04, Department of Neurology, Centre Mémoire de Ressources et Recherche, Nantes, France; Nuclear Medicine Department (E.G.), Aix-Marseille University, APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, France; APHM (M.D.), Timone, Service de Neurologie et Neuropsychologie, APHM-Hôpital Timone Adultes, Marseille, France; and Aix-Marseille Univ (M.D.), INSERM, INS Institut de Neurosciences des Systèmes, France
| | - Valérie Causse-Lemercier
- From the Sorbonne Université (D.S., L.S., M.H., A.F., D.R., M.L., R.M., I.L.B.), Paris Brain Institute-Institut du Cerveau-ICM, Inserm U1127, CNRS UMR 7225, Paris, France; IM2A (D.S., M.H., A.F., D.R., C.A., R.M., I.L.B.), Reference Centre for Rare or Early-Onset Dementias, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Aramis Project Team (D.S.), Inria Research Center of Paris, France; Sorbonne Université (H.B., M.P.-I., M.L., A.K., M.-O.H.), CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, LIB, Paris, France; Centre d'Acquisition et de Traitement d'Images (CATI) (H.B., M.L., A.K., M.-O.H.), US52-UAR2031, CEA, ICM, SU, CNRS, INSERM, APHP, Ile de France, France; Université Paris-Saclay (H.B.), CEA, CNRS, Neurospin, UMR9027 Baobab, Gif-sur-Yvette, France; Centre of Excellence of Neurodegenerative Disease (CoEN) (M.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Département de Médecine Nucléaire (V.C.-L., A.K., M.-O.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Nuclear Medicine Department (A.J.), CHU Lille, Lille, France; Univ Lille (F.P.), Inserm U1172, CHU Lille, DistAlz, LiCEND, CNR-MAJ, France; Department of Nuclear Medicine (M.C.), Centre Henri Becquerel, Rouen University Hospital, France; Normandie Univ (D.W.), UNIROUEN, Inserm U1245 and CHU Rouen, Department of Neurology, CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, CIC-CRB1404, Rouen, France; Nuclear Medicine Department (A.H.), Toulouse Purpan University Hospital, France; Department of Neurology and ToNIC (J.P.), Toulouse NeuroImaging Centre, Inserm, UPS, Toulouse University Hospital, France; Nuclear Medicine Department (A.P.), University Hospital of Nantes, France; CHU Nantes (C.B.-B.), Inserm CIC04, Department of Neurology, Centre Mémoire de Ressources et Recherche, Nantes, France; Nuclear Medicine Department (E.G.), Aix-Marseille University, APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, France; APHM (M.D.), Timone, Service de Neurologie et Neuropsychologie, APHM-Hôpital Timone Adultes, Marseille, France; and Aix-Marseille Univ (M.D.), INSERM, INS Institut de Neurosciences des Systèmes, France
| | - Alice Jaillard
- From the Sorbonne Université (D.S., L.S., M.H., A.F., D.R., M.L., R.M., I.L.B.), Paris Brain Institute-Institut du Cerveau-ICM, Inserm U1127, CNRS UMR 7225, Paris, France; IM2A (D.S., M.H., A.F., D.R., C.A., R.M., I.L.B.), Reference Centre for Rare or Early-Onset Dementias, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Aramis Project Team (D.S.), Inria Research Center of Paris, France; Sorbonne Université (H.B., M.P.-I., M.L., A.K., M.-O.H.), CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, LIB, Paris, France; Centre d'Acquisition et de Traitement d'Images (CATI) (H.B., M.L., A.K., M.-O.H.), US52-UAR2031, CEA, ICM, SU, CNRS, INSERM, APHP, Ile de France, France; Université Paris-Saclay (H.B.), CEA, CNRS, Neurospin, UMR9027 Baobab, Gif-sur-Yvette, France; Centre of Excellence of Neurodegenerative Disease (CoEN) (M.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Département de Médecine Nucléaire (V.C.-L., A.K., M.-O.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Nuclear Medicine Department (A.J.), CHU Lille, Lille, France; Univ Lille (F.P.), Inserm U1172, CHU Lille, DistAlz, LiCEND, CNR-MAJ, France; Department of Nuclear Medicine (M.C.), Centre Henri Becquerel, Rouen University Hospital, France; Normandie Univ (D.W.), UNIROUEN, Inserm U1245 and CHU Rouen, Department of Neurology, CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, CIC-CRB1404, Rouen, France; Nuclear Medicine Department (A.H.), Toulouse Purpan University Hospital, France; Department of Neurology and ToNIC (J.P.), Toulouse NeuroImaging Centre, Inserm, UPS, Toulouse University Hospital, France; Nuclear Medicine Department (A.P.), University Hospital of Nantes, France; CHU Nantes (C.B.-B.), Inserm CIC04, Department of Neurology, Centre Mémoire de Ressources et Recherche, Nantes, France; Nuclear Medicine Department (E.G.), Aix-Marseille University, APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, France; APHM (M.D.), Timone, Service de Neurologie et Neuropsychologie, APHM-Hôpital Timone Adultes, Marseille, France; and Aix-Marseille Univ (M.D.), INSERM, INS Institut de Neurosciences des Systèmes, France
| | - Florence Pasquier
- From the Sorbonne Université (D.S., L.S., M.H., A.F., D.R., M.L., R.M., I.L.B.), Paris Brain Institute-Institut du Cerveau-ICM, Inserm U1127, CNRS UMR 7225, Paris, France; IM2A (D.S., M.H., A.F., D.R., C.A., R.M., I.L.B.), Reference Centre for Rare or Early-Onset Dementias, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Aramis Project Team (D.S.), Inria Research Center of Paris, France; Sorbonne Université (H.B., M.P.-I., M.L., A.K., M.-O.H.), CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, LIB, Paris, France; Centre d'Acquisition et de Traitement d'Images (CATI) (H.B., M.L., A.K., M.-O.H.), US52-UAR2031, CEA, ICM, SU, CNRS, INSERM, APHP, Ile de France, France; Université Paris-Saclay (H.B.), CEA, CNRS, Neurospin, UMR9027 Baobab, Gif-sur-Yvette, France; Centre of Excellence of Neurodegenerative Disease (CoEN) (M.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Département de Médecine Nucléaire (V.C.-L., A.K., M.-O.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Nuclear Medicine Department (A.J.), CHU Lille, Lille, France; Univ Lille (F.P.), Inserm U1172, CHU Lille, DistAlz, LiCEND, CNR-MAJ, France; Department of Nuclear Medicine (M.C.), Centre Henri Becquerel, Rouen University Hospital, France; Normandie Univ (D.W.), UNIROUEN, Inserm U1245 and CHU Rouen, Department of Neurology, CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, CIC-CRB1404, Rouen, France; Nuclear Medicine Department (A.H.), Toulouse Purpan University Hospital, France; Department of Neurology and ToNIC (J.P.), Toulouse NeuroImaging Centre, Inserm, UPS, Toulouse University Hospital, France; Nuclear Medicine Department (A.P.), University Hospital of Nantes, France; CHU Nantes (C.B.-B.), Inserm CIC04, Department of Neurology, Centre Mémoire de Ressources et Recherche, Nantes, France; Nuclear Medicine Department (E.G.), Aix-Marseille University, APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, France; APHM (M.D.), Timone, Service de Neurologie et Neuropsychologie, APHM-Hôpital Timone Adultes, Marseille, France; and Aix-Marseille Univ (M.D.), INSERM, INS Institut de Neurosciences des Systèmes, France
| | - Mathieu Chastan
- From the Sorbonne Université (D.S., L.S., M.H., A.F., D.R., M.L., R.M., I.L.B.), Paris Brain Institute-Institut du Cerveau-ICM, Inserm U1127, CNRS UMR 7225, Paris, France; IM2A (D.S., M.H., A.F., D.R., C.A., R.M., I.L.B.), Reference Centre for Rare or Early-Onset Dementias, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Aramis Project Team (D.S.), Inria Research Center of Paris, France; Sorbonne Université (H.B., M.P.-I., M.L., A.K., M.-O.H.), CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, LIB, Paris, France; Centre d'Acquisition et de Traitement d'Images (CATI) (H.B., M.L., A.K., M.-O.H.), US52-UAR2031, CEA, ICM, SU, CNRS, INSERM, APHP, Ile de France, France; Université Paris-Saclay (H.B.), CEA, CNRS, Neurospin, UMR9027 Baobab, Gif-sur-Yvette, France; Centre of Excellence of Neurodegenerative Disease (CoEN) (M.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Département de Médecine Nucléaire (V.C.-L., A.K., M.-O.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Nuclear Medicine Department (A.J.), CHU Lille, Lille, France; Univ Lille (F.P.), Inserm U1172, CHU Lille, DistAlz, LiCEND, CNR-MAJ, France; Department of Nuclear Medicine (M.C.), Centre Henri Becquerel, Rouen University Hospital, France; Normandie Univ (D.W.), UNIROUEN, Inserm U1245 and CHU Rouen, Department of Neurology, CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, CIC-CRB1404, Rouen, France; Nuclear Medicine Department (A.H.), Toulouse Purpan University Hospital, France; Department of Neurology and ToNIC (J.P.), Toulouse NeuroImaging Centre, Inserm, UPS, Toulouse University Hospital, France; Nuclear Medicine Department (A.P.), University Hospital of Nantes, France; CHU Nantes (C.B.-B.), Inserm CIC04, Department of Neurology, Centre Mémoire de Ressources et Recherche, Nantes, France; Nuclear Medicine Department (E.G.), Aix-Marseille University, APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, France; APHM (M.D.), Timone, Service de Neurologie et Neuropsychologie, APHM-Hôpital Timone Adultes, Marseille, France; and Aix-Marseille Univ (M.D.), INSERM, INS Institut de Neurosciences des Systèmes, France
| | - David Wallon
- From the Sorbonne Université (D.S., L.S., M.H., A.F., D.R., M.L., R.M., I.L.B.), Paris Brain Institute-Institut du Cerveau-ICM, Inserm U1127, CNRS UMR 7225, Paris, France; IM2A (D.S., M.H., A.F., D.R., C.A., R.M., I.L.B.), Reference Centre for Rare or Early-Onset Dementias, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Aramis Project Team (D.S.), Inria Research Center of Paris, France; Sorbonne Université (H.B., M.P.-I., M.L., A.K., M.-O.H.), CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, LIB, Paris, France; Centre d'Acquisition et de Traitement d'Images (CATI) (H.B., M.L., A.K., M.-O.H.), US52-UAR2031, CEA, ICM, SU, CNRS, INSERM, APHP, Ile de France, France; Université Paris-Saclay (H.B.), CEA, CNRS, Neurospin, UMR9027 Baobab, Gif-sur-Yvette, France; Centre of Excellence of Neurodegenerative Disease (CoEN) (M.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Département de Médecine Nucléaire (V.C.-L., A.K., M.-O.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Nuclear Medicine Department (A.J.), CHU Lille, Lille, France; Univ Lille (F.P.), Inserm U1172, CHU Lille, DistAlz, LiCEND, CNR-MAJ, France; Department of Nuclear Medicine (M.C.), Centre Henri Becquerel, Rouen University Hospital, France; Normandie Univ (D.W.), UNIROUEN, Inserm U1245 and CHU Rouen, Department of Neurology, CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, CIC-CRB1404, Rouen, France; Nuclear Medicine Department (A.H.), Toulouse Purpan University Hospital, France; Department of Neurology and ToNIC (J.P.), Toulouse NeuroImaging Centre, Inserm, UPS, Toulouse University Hospital, France; Nuclear Medicine Department (A.P.), University Hospital of Nantes, France; CHU Nantes (C.B.-B.), Inserm CIC04, Department of Neurology, Centre Mémoire de Ressources et Recherche, Nantes, France; Nuclear Medicine Department (E.G.), Aix-Marseille University, APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, France; APHM (M.D.), Timone, Service de Neurologie et Neuropsychologie, APHM-Hôpital Timone Adultes, Marseille, France; and Aix-Marseille Univ (M.D.), INSERM, INS Institut de Neurosciences des Systèmes, France
| | - Anne Hitzel
- From the Sorbonne Université (D.S., L.S., M.H., A.F., D.R., M.L., R.M., I.L.B.), Paris Brain Institute-Institut du Cerveau-ICM, Inserm U1127, CNRS UMR 7225, Paris, France; IM2A (D.S., M.H., A.F., D.R., C.A., R.M., I.L.B.), Reference Centre for Rare or Early-Onset Dementias, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Aramis Project Team (D.S.), Inria Research Center of Paris, France; Sorbonne Université (H.B., M.P.-I., M.L., A.K., M.-O.H.), CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, LIB, Paris, France; Centre d'Acquisition et de Traitement d'Images (CATI) (H.B., M.L., A.K., M.-O.H.), US52-UAR2031, CEA, ICM, SU, CNRS, INSERM, APHP, Ile de France, France; Université Paris-Saclay (H.B.), CEA, CNRS, Neurospin, UMR9027 Baobab, Gif-sur-Yvette, France; Centre of Excellence of Neurodegenerative Disease (CoEN) (M.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Département de Médecine Nucléaire (V.C.-L., A.K., M.-O.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Nuclear Medicine Department (A.J.), CHU Lille, Lille, France; Univ Lille (F.P.), Inserm U1172, CHU Lille, DistAlz, LiCEND, CNR-MAJ, France; Department of Nuclear Medicine (M.C.), Centre Henri Becquerel, Rouen University Hospital, France; Normandie Univ (D.W.), UNIROUEN, Inserm U1245 and CHU Rouen, Department of Neurology, CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, CIC-CRB1404, Rouen, France; Nuclear Medicine Department (A.H.), Toulouse Purpan University Hospital, France; Department of Neurology and ToNIC (J.P.), Toulouse NeuroImaging Centre, Inserm, UPS, Toulouse University Hospital, France; Nuclear Medicine Department (A.P.), University Hospital of Nantes, France; CHU Nantes (C.B.-B.), Inserm CIC04, Department of Neurology, Centre Mémoire de Ressources et Recherche, Nantes, France; Nuclear Medicine Department (E.G.), Aix-Marseille University, APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, France; APHM (M.D.), Timone, Service de Neurologie et Neuropsychologie, APHM-Hôpital Timone Adultes, Marseille, France; and Aix-Marseille Univ (M.D.), INSERM, INS Institut de Neurosciences des Systèmes, France
| | - Jérémie Pariente
- From the Sorbonne Université (D.S., L.S., M.H., A.F., D.R., M.L., R.M., I.L.B.), Paris Brain Institute-Institut du Cerveau-ICM, Inserm U1127, CNRS UMR 7225, Paris, France; IM2A (D.S., M.H., A.F., D.R., C.A., R.M., I.L.B.), Reference Centre for Rare or Early-Onset Dementias, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Aramis Project Team (D.S.), Inria Research Center of Paris, France; Sorbonne Université (H.B., M.P.-I., M.L., A.K., M.-O.H.), CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, LIB, Paris, France; Centre d'Acquisition et de Traitement d'Images (CATI) (H.B., M.L., A.K., M.-O.H.), US52-UAR2031, CEA, ICM, SU, CNRS, INSERM, APHP, Ile de France, France; Université Paris-Saclay (H.B.), CEA, CNRS, Neurospin, UMR9027 Baobab, Gif-sur-Yvette, France; Centre of Excellence of Neurodegenerative Disease (CoEN) (M.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Département de Médecine Nucléaire (V.C.-L., A.K., M.-O.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Nuclear Medicine Department (A.J.), CHU Lille, Lille, France; Univ Lille (F.P.), Inserm U1172, CHU Lille, DistAlz, LiCEND, CNR-MAJ, France; Department of Nuclear Medicine (M.C.), Centre Henri Becquerel, Rouen University Hospital, France; Normandie Univ (D.W.), UNIROUEN, Inserm U1245 and CHU Rouen, Department of Neurology, CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, CIC-CRB1404, Rouen, France; Nuclear Medicine Department (A.H.), Toulouse Purpan University Hospital, France; Department of Neurology and ToNIC (J.P.), Toulouse NeuroImaging Centre, Inserm, UPS, Toulouse University Hospital, France; Nuclear Medicine Department (A.P.), University Hospital of Nantes, France; CHU Nantes (C.B.-B.), Inserm CIC04, Department of Neurology, Centre Mémoire de Ressources et Recherche, Nantes, France; Nuclear Medicine Department (E.G.), Aix-Marseille University, APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, France; APHM (M.D.), Timone, Service de Neurologie et Neuropsychologie, APHM-Hôpital Timone Adultes, Marseille, France; and Aix-Marseille Univ (M.D.), INSERM, INS Institut de Neurosciences des Systèmes, France
| | - Amandine Pallardy
- From the Sorbonne Université (D.S., L.S., M.H., A.F., D.R., M.L., R.M., I.L.B.), Paris Brain Institute-Institut du Cerveau-ICM, Inserm U1127, CNRS UMR 7225, Paris, France; IM2A (D.S., M.H., A.F., D.R., C.A., R.M., I.L.B.), Reference Centre for Rare or Early-Onset Dementias, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Aramis Project Team (D.S.), Inria Research Center of Paris, France; Sorbonne Université (H.B., M.P.-I., M.L., A.K., M.-O.H.), CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, LIB, Paris, France; Centre d'Acquisition et de Traitement d'Images (CATI) (H.B., M.L., A.K., M.-O.H.), US52-UAR2031, CEA, ICM, SU, CNRS, INSERM, APHP, Ile de France, France; Université Paris-Saclay (H.B.), CEA, CNRS, Neurospin, UMR9027 Baobab, Gif-sur-Yvette, France; Centre of Excellence of Neurodegenerative Disease (CoEN) (M.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Département de Médecine Nucléaire (V.C.-L., A.K., M.-O.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Nuclear Medicine Department (A.J.), CHU Lille, Lille, France; Univ Lille (F.P.), Inserm U1172, CHU Lille, DistAlz, LiCEND, CNR-MAJ, France; Department of Nuclear Medicine (M.C.), Centre Henri Becquerel, Rouen University Hospital, France; Normandie Univ (D.W.), UNIROUEN, Inserm U1245 and CHU Rouen, Department of Neurology, CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, CIC-CRB1404, Rouen, France; Nuclear Medicine Department (A.H.), Toulouse Purpan University Hospital, France; Department of Neurology and ToNIC (J.P.), Toulouse NeuroImaging Centre, Inserm, UPS, Toulouse University Hospital, France; Nuclear Medicine Department (A.P.), University Hospital of Nantes, France; CHU Nantes (C.B.-B.), Inserm CIC04, Department of Neurology, Centre Mémoire de Ressources et Recherche, Nantes, France; Nuclear Medicine Department (E.G.), Aix-Marseille University, APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, France; APHM (M.D.), Timone, Service de Neurologie et Neuropsychologie, APHM-Hôpital Timone Adultes, Marseille, France; and Aix-Marseille Univ (M.D.), INSERM, INS Institut de Neurosciences des Systèmes, France
| | - Claire Boutoleau-Bretonnière
- From the Sorbonne Université (D.S., L.S., M.H., A.F., D.R., M.L., R.M., I.L.B.), Paris Brain Institute-Institut du Cerveau-ICM, Inserm U1127, CNRS UMR 7225, Paris, France; IM2A (D.S., M.H., A.F., D.R., C.A., R.M., I.L.B.), Reference Centre for Rare or Early-Onset Dementias, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Aramis Project Team (D.S.), Inria Research Center of Paris, France; Sorbonne Université (H.B., M.P.-I., M.L., A.K., M.-O.H.), CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, LIB, Paris, France; Centre d'Acquisition et de Traitement d'Images (CATI) (H.B., M.L., A.K., M.-O.H.), US52-UAR2031, CEA, ICM, SU, CNRS, INSERM, APHP, Ile de France, France; Université Paris-Saclay (H.B.), CEA, CNRS, Neurospin, UMR9027 Baobab, Gif-sur-Yvette, France; Centre of Excellence of Neurodegenerative Disease (CoEN) (M.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Département de Médecine Nucléaire (V.C.-L., A.K., M.-O.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Nuclear Medicine Department (A.J.), CHU Lille, Lille, France; Univ Lille (F.P.), Inserm U1172, CHU Lille, DistAlz, LiCEND, CNR-MAJ, France; Department of Nuclear Medicine (M.C.), Centre Henri Becquerel, Rouen University Hospital, France; Normandie Univ (D.W.), UNIROUEN, Inserm U1245 and CHU Rouen, Department of Neurology, CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, CIC-CRB1404, Rouen, France; Nuclear Medicine Department (A.H.), Toulouse Purpan University Hospital, France; Department of Neurology and ToNIC (J.P.), Toulouse NeuroImaging Centre, Inserm, UPS, Toulouse University Hospital, France; Nuclear Medicine Department (A.P.), University Hospital of Nantes, France; CHU Nantes (C.B.-B.), Inserm CIC04, Department of Neurology, Centre Mémoire de Ressources et Recherche, Nantes, France; Nuclear Medicine Department (E.G.), Aix-Marseille University, APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, France; APHM (M.D.), Timone, Service de Neurologie et Neuropsychologie, APHM-Hôpital Timone Adultes, Marseille, France; and Aix-Marseille Univ (M.D.), INSERM, INS Institut de Neurosciences des Systèmes, France
| | - Eric Guedj
- From the Sorbonne Université (D.S., L.S., M.H., A.F., D.R., M.L., R.M., I.L.B.), Paris Brain Institute-Institut du Cerveau-ICM, Inserm U1127, CNRS UMR 7225, Paris, France; IM2A (D.S., M.H., A.F., D.R., C.A., R.M., I.L.B.), Reference Centre for Rare or Early-Onset Dementias, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Aramis Project Team (D.S.), Inria Research Center of Paris, France; Sorbonne Université (H.B., M.P.-I., M.L., A.K., M.-O.H.), CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, LIB, Paris, France; Centre d'Acquisition et de Traitement d'Images (CATI) (H.B., M.L., A.K., M.-O.H.), US52-UAR2031, CEA, ICM, SU, CNRS, INSERM, APHP, Ile de France, France; Université Paris-Saclay (H.B.), CEA, CNRS, Neurospin, UMR9027 Baobab, Gif-sur-Yvette, France; Centre of Excellence of Neurodegenerative Disease (CoEN) (M.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Département de Médecine Nucléaire (V.C.-L., A.K., M.-O.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Nuclear Medicine Department (A.J.), CHU Lille, Lille, France; Univ Lille (F.P.), Inserm U1172, CHU Lille, DistAlz, LiCEND, CNR-MAJ, France; Department of Nuclear Medicine (M.C.), Centre Henri Becquerel, Rouen University Hospital, France; Normandie Univ (D.W.), UNIROUEN, Inserm U1245 and CHU Rouen, Department of Neurology, CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, CIC-CRB1404, Rouen, France; Nuclear Medicine Department (A.H.), Toulouse Purpan University Hospital, France; Department of Neurology and ToNIC (J.P.), Toulouse NeuroImaging Centre, Inserm, UPS, Toulouse University Hospital, France; Nuclear Medicine Department (A.P.), University Hospital of Nantes, France; CHU Nantes (C.B.-B.), Inserm CIC04, Department of Neurology, Centre Mémoire de Ressources et Recherche, Nantes, France; Nuclear Medicine Department (E.G.), Aix-Marseille University, APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, France; APHM (M.D.), Timone, Service de Neurologie et Neuropsychologie, APHM-Hôpital Timone Adultes, Marseille, France; and Aix-Marseille Univ (M.D.), INSERM, INS Institut de Neurosciences des Systèmes, France
| | - Mira Didic
- From the Sorbonne Université (D.S., L.S., M.H., A.F., D.R., M.L., R.M., I.L.B.), Paris Brain Institute-Institut du Cerveau-ICM, Inserm U1127, CNRS UMR 7225, Paris, France; IM2A (D.S., M.H., A.F., D.R., C.A., R.M., I.L.B.), Reference Centre for Rare or Early-Onset Dementias, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Aramis Project Team (D.S.), Inria Research Center of Paris, France; Sorbonne Université (H.B., M.P.-I., M.L., A.K., M.-O.H.), CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, LIB, Paris, France; Centre d'Acquisition et de Traitement d'Images (CATI) (H.B., M.L., A.K., M.-O.H.), US52-UAR2031, CEA, ICM, SU, CNRS, INSERM, APHP, Ile de France, France; Université Paris-Saclay (H.B.), CEA, CNRS, Neurospin, UMR9027 Baobab, Gif-sur-Yvette, France; Centre of Excellence of Neurodegenerative Disease (CoEN) (M.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Département de Médecine Nucléaire (V.C.-L., A.K., M.-O.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Nuclear Medicine Department (A.J.), CHU Lille, Lille, France; Univ Lille (F.P.), Inserm U1172, CHU Lille, DistAlz, LiCEND, CNR-MAJ, France; Department of Nuclear Medicine (M.C.), Centre Henri Becquerel, Rouen University Hospital, France; Normandie Univ (D.W.), UNIROUEN, Inserm U1245 and CHU Rouen, Department of Neurology, CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, CIC-CRB1404, Rouen, France; Nuclear Medicine Department (A.H.), Toulouse Purpan University Hospital, France; Department of Neurology and ToNIC (J.P.), Toulouse NeuroImaging Centre, Inserm, UPS, Toulouse University Hospital, France; Nuclear Medicine Department (A.P.), University Hospital of Nantes, France; CHU Nantes (C.B.-B.), Inserm CIC04, Department of Neurology, Centre Mémoire de Ressources et Recherche, Nantes, France; Nuclear Medicine Department (E.G.), Aix-Marseille University, APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, France; APHM (M.D.), Timone, Service de Neurologie et Neuropsychologie, APHM-Hôpital Timone Adultes, Marseille, France; and Aix-Marseille Univ (M.D.), INSERM, INS Institut de Neurosciences des Systèmes, France
| | - Raffaella Migliaccio
- From the Sorbonne Université (D.S., L.S., M.H., A.F., D.R., M.L., R.M., I.L.B.), Paris Brain Institute-Institut du Cerveau-ICM, Inserm U1127, CNRS UMR 7225, Paris, France; IM2A (D.S., M.H., A.F., D.R., C.A., R.M., I.L.B.), Reference Centre for Rare or Early-Onset Dementias, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Aramis Project Team (D.S.), Inria Research Center of Paris, France; Sorbonne Université (H.B., M.P.-I., M.L., A.K., M.-O.H.), CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, LIB, Paris, France; Centre d'Acquisition et de Traitement d'Images (CATI) (H.B., M.L., A.K., M.-O.H.), US52-UAR2031, CEA, ICM, SU, CNRS, INSERM, APHP, Ile de France, France; Université Paris-Saclay (H.B.), CEA, CNRS, Neurospin, UMR9027 Baobab, Gif-sur-Yvette, France; Centre of Excellence of Neurodegenerative Disease (CoEN) (M.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Département de Médecine Nucléaire (V.C.-L., A.K., M.-O.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Nuclear Medicine Department (A.J.), CHU Lille, Lille, France; Univ Lille (F.P.), Inserm U1172, CHU Lille, DistAlz, LiCEND, CNR-MAJ, France; Department of Nuclear Medicine (M.C.), Centre Henri Becquerel, Rouen University Hospital, France; Normandie Univ (D.W.), UNIROUEN, Inserm U1245 and CHU Rouen, Department of Neurology, CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, CIC-CRB1404, Rouen, France; Nuclear Medicine Department (A.H.), Toulouse Purpan University Hospital, France; Department of Neurology and ToNIC (J.P.), Toulouse NeuroImaging Centre, Inserm, UPS, Toulouse University Hospital, France; Nuclear Medicine Department (A.P.), University Hospital of Nantes, France; CHU Nantes (C.B.-B.), Inserm CIC04, Department of Neurology, Centre Mémoire de Ressources et Recherche, Nantes, France; Nuclear Medicine Department (E.G.), Aix-Marseille University, APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, France; APHM (M.D.), Timone, Service de Neurologie et Neuropsychologie, APHM-Hôpital Timone Adultes, Marseille, France; and Aix-Marseille Univ (M.D.), INSERM, INS Institut de Neurosciences des Systèmes, France
| | - Aurélie Kas
- From the Sorbonne Université (D.S., L.S., M.H., A.F., D.R., M.L., R.M., I.L.B.), Paris Brain Institute-Institut du Cerveau-ICM, Inserm U1127, CNRS UMR 7225, Paris, France; IM2A (D.S., M.H., A.F., D.R., C.A., R.M., I.L.B.), Reference Centre for Rare or Early-Onset Dementias, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Aramis Project Team (D.S.), Inria Research Center of Paris, France; Sorbonne Université (H.B., M.P.-I., M.L., A.K., M.-O.H.), CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, LIB, Paris, France; Centre d'Acquisition et de Traitement d'Images (CATI) (H.B., M.L., A.K., M.-O.H.), US52-UAR2031, CEA, ICM, SU, CNRS, INSERM, APHP, Ile de France, France; Université Paris-Saclay (H.B.), CEA, CNRS, Neurospin, UMR9027 Baobab, Gif-sur-Yvette, France; Centre of Excellence of Neurodegenerative Disease (CoEN) (M.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Département de Médecine Nucléaire (V.C.-L., A.K., M.-O.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Nuclear Medicine Department (A.J.), CHU Lille, Lille, France; Univ Lille (F.P.), Inserm U1172, CHU Lille, DistAlz, LiCEND, CNR-MAJ, France; Department of Nuclear Medicine (M.C.), Centre Henri Becquerel, Rouen University Hospital, France; Normandie Univ (D.W.), UNIROUEN, Inserm U1245 and CHU Rouen, Department of Neurology, CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, CIC-CRB1404, Rouen, France; Nuclear Medicine Department (A.H.), Toulouse Purpan University Hospital, France; Department of Neurology and ToNIC (J.P.), Toulouse NeuroImaging Centre, Inserm, UPS, Toulouse University Hospital, France; Nuclear Medicine Department (A.P.), University Hospital of Nantes, France; CHU Nantes (C.B.-B.), Inserm CIC04, Department of Neurology, Centre Mémoire de Ressources et Recherche, Nantes, France; Nuclear Medicine Department (E.G.), Aix-Marseille University, APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, France; APHM (M.D.), Timone, Service de Neurologie et Neuropsychologie, APHM-Hôpital Timone Adultes, Marseille, France; and Aix-Marseille Univ (M.D.), INSERM, INS Institut de Neurosciences des Systèmes, France
| | - Marie-Odile Habert
- From the Sorbonne Université (D.S., L.S., M.H., A.F., D.R., M.L., R.M., I.L.B.), Paris Brain Institute-Institut du Cerveau-ICM, Inserm U1127, CNRS UMR 7225, Paris, France; IM2A (D.S., M.H., A.F., D.R., C.A., R.M., I.L.B.), Reference Centre for Rare or Early-Onset Dementias, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Aramis Project Team (D.S.), Inria Research Center of Paris, France; Sorbonne Université (H.B., M.P.-I., M.L., A.K., M.-O.H.), CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, LIB, Paris, France; Centre d'Acquisition et de Traitement d'Images (CATI) (H.B., M.L., A.K., M.-O.H.), US52-UAR2031, CEA, ICM, SU, CNRS, INSERM, APHP, Ile de France, France; Université Paris-Saclay (H.B.), CEA, CNRS, Neurospin, UMR9027 Baobab, Gif-sur-Yvette, France; Centre of Excellence of Neurodegenerative Disease (CoEN) (M.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Département de Médecine Nucléaire (V.C.-L., A.K., M.-O.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Nuclear Medicine Department (A.J.), CHU Lille, Lille, France; Univ Lille (F.P.), Inserm U1172, CHU Lille, DistAlz, LiCEND, CNR-MAJ, France; Department of Nuclear Medicine (M.C.), Centre Henri Becquerel, Rouen University Hospital, France; Normandie Univ (D.W.), UNIROUEN, Inserm U1245 and CHU Rouen, Department of Neurology, CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, CIC-CRB1404, Rouen, France; Nuclear Medicine Department (A.H.), Toulouse Purpan University Hospital, France; Department of Neurology and ToNIC (J.P.), Toulouse NeuroImaging Centre, Inserm, UPS, Toulouse University Hospital, France; Nuclear Medicine Department (A.P.), University Hospital of Nantes, France; CHU Nantes (C.B.-B.), Inserm CIC04, Department of Neurology, Centre Mémoire de Ressources et Recherche, Nantes, France; Nuclear Medicine Department (E.G.), Aix-Marseille University, APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, France; APHM (M.D.), Timone, Service de Neurologie et Neuropsychologie, APHM-Hôpital Timone Adultes, Marseille, France; and Aix-Marseille Univ (M.D.), INSERM, INS Institut de Neurosciences des Systèmes, France
| | - Isabelle Le Ber
- From the Sorbonne Université (D.S., L.S., M.H., A.F., D.R., M.L., R.M., I.L.B.), Paris Brain Institute-Institut du Cerveau-ICM, Inserm U1127, CNRS UMR 7225, Paris, France; IM2A (D.S., M.H., A.F., D.R., C.A., R.M., I.L.B.), Reference Centre for Rare or Early-Onset Dementias, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Aramis Project Team (D.S.), Inria Research Center of Paris, France; Sorbonne Université (H.B., M.P.-I., M.L., A.K., M.-O.H.), CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, LIB, Paris, France; Centre d'Acquisition et de Traitement d'Images (CATI) (H.B., M.L., A.K., M.-O.H.), US52-UAR2031, CEA, ICM, SU, CNRS, INSERM, APHP, Ile de France, France; Université Paris-Saclay (H.B.), CEA, CNRS, Neurospin, UMR9027 Baobab, Gif-sur-Yvette, France; Centre of Excellence of Neurodegenerative Disease (CoEN) (M.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Département de Médecine Nucléaire (V.C.-L., A.K., M.-O.H.), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Nuclear Medicine Department (A.J.), CHU Lille, Lille, France; Univ Lille (F.P.), Inserm U1172, CHU Lille, DistAlz, LiCEND, CNR-MAJ, France; Department of Nuclear Medicine (M.C.), Centre Henri Becquerel, Rouen University Hospital, France; Normandie Univ (D.W.), UNIROUEN, Inserm U1245 and CHU Rouen, Department of Neurology, CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, CIC-CRB1404, Rouen, France; Nuclear Medicine Department (A.H.), Toulouse Purpan University Hospital, France; Department of Neurology and ToNIC (J.P.), Toulouse NeuroImaging Centre, Inserm, UPS, Toulouse University Hospital, France; Nuclear Medicine Department (A.P.), University Hospital of Nantes, France; CHU Nantes (C.B.-B.), Inserm CIC04, Department of Neurology, Centre Mémoire de Ressources et Recherche, Nantes, France; Nuclear Medicine Department (E.G.), Aix-Marseille University, APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, France; APHM (M.D.), Timone, Service de Neurologie et Neuropsychologie, APHM-Hôpital Timone Adultes, Marseille, France; and Aix-Marseille Univ (M.D.), INSERM, INS Institut de Neurosciences des Systèmes, France.
| | | |
Collapse
|
2
|
Lee H, Mackenzie IRA, Beg MF, Popuri K, Rademakers R, Wittenberg D, Hsiung GYR. White-matter abnormalities in presymptomatic GRN and C9orf72 mutation carriers. Brain Commun 2022; 5:fcac333. [PMID: 36632182 PMCID: PMC9825756 DOI: 10.1093/braincomms/fcac333] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2022] [Revised: 08/26/2022] [Accepted: 12/18/2022] [Indexed: 12/23/2022] Open
Abstract
A large proportion of familial frontotemporal dementia is caused by TAR DNA-binding protein 43 (transactive response DNA-binding protein 43 kDa) proteinopathies. Accordingly, carriers of autosomal dominant mutations in the genes associated with TAR DNA-binding protein 43 aggregation, such as Chromosome 9 open reading frame 72 (C9orf72) or progranulin (GRN), are at risk of later developing frontotemporal dementia. Brain imaging abnormalities that develop before dementia onset in mutation carriers may serve as proxies for the presymptomatic stages of familial frontotemporal dementia due to a genetic cause. Our study objective was to investigate brain MRI-based white-matter changes in predementia participants carrying mutations in C9orf72 or GRN genes. We analysed mutation carriers and their family member controls (noncarriers) from the University of British Columbia familial frontotemporal dementia study. First, a total of 42 participants (8 GRN carriers; 11 C9orf72 carriers; 23 noncarriers) had longitudinal T1-weighted MRI over ∼2 years. White-matter signal hypointensities were segmented and volumes were calculated for each participant. General linear models were applied to compare the baseline burden and the annualized rate of accumulation of signal abnormalities among mutation carriers and noncarriers. Second, a total of 60 participants (9 GRN carriers; 17 C9orf72 carriers; 34 noncarriers) had cross-sectional diffusion tensor MRI available. For each participant, we calculated the average fractional anisotropy and mean, radial and axial diffusivity parameter values within the normal-appearing white-matter tissues. General linear models were applied to compare whether mutation carriers and noncarriers had different trends in diffusion tensor imaging parameter values as they neared the expected age of onset. Baseline volumes of white-matter signal abnormalities were not significantly different among mutation carriers and noncarriers. Longitudinally, GRN carriers had significantly higher annualized rates of accumulation (estimated mean: 15.87%/year) compared with C9orf72 carriers (3.69%/year) or noncarriers (2.64%/year). A significant relationship between diffusion tensor imaging parameter values and increasing expected age of onset was found in the periventricular normal-appearing white-matter region. Specifically, GRN carriers had a tendency of a faster increase of mean and radial diffusivity values and C9orf72 carriers had a tendency of a faster decline of fractional anisotropy values as they reached closer to the expected age of dementia onset. These findings suggest that white-matter changes may represent early markers of familial frontotemporal dementia due to genetic causes. However, GRN and C9orf72 mutation carriers may have different mechanisms leading to tissue abnormalities.
Collapse
Affiliation(s)
- Hyunwoo Lee
- Correspondence to: Hyunwoo Lee S154-2211 Wesbrook Mall Vancouver, B.C., Canada V6T 2B5 E-mail:
| | - Ian R A Mackenzie
- Department of Pathology and Laboratory Medicine, Faculty of Medicine, University of British Columbia, Vancouver V6T2B5, Canada
| | - Mirza Faisal Beg
- School of Engineering Science, Simon Fraser University, Burnaby V5A1S6, Canada
| | - Karteek Popuri
- Department of Computer Science, Memorial University of Newfoundland, St John’s A1B3X5, Canada
| | - Rosa Rademakers
- Applied and Translational Neurogenomics, VIB Center for Molecular Neurology, VIB, Antwerp 2610, Belgium,Department of Biomedical Sciences, University of Antwerp, Antwerp 2610, Belgium,Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA
| | - Dana Wittenberg
- Division of Neurology, Department of Medicine, University of British Columbia, Vancouver V6T2B5, Canada
| | - Ging-Yuek Robin Hsiung
- Division of Neurology, Department of Medicine, University of British Columbia, Vancouver V6T2B5, Canada
| |
Collapse
|
3
|
Finger E, Malik R, Bocchetta M, Coleman K, Graff C, Borroni B, Masellis M, Laforce R, Greaves CV, Russell LL, Convery RS, Bouzigues A, Cash DM, Otto M, Synofzik M, Rowe JB, Galimberti D, Tiraboschi P, Bartha R, Shoesmith C, Tartaglia MC, van Swieten JC, Seelaar H, Jiskoo LC, Sorbi S, Butler CR, Gerhard A, Sanchez-Valle R, de Mendonça A, Moreno F, Vandenberghe R, Le Ber I, Levin J, Pasquier F, Santana I, Rohrer JD, Ducharme S. Neurodevelopmental effects of genetic frontotemporal dementia in young adult mutation carriers. Brain 2022; 146:2120-2131. [PMID: 36458975 DOI: 10.1093/brain/awac446] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2022] [Revised: 10/05/2022] [Accepted: 10/16/2022] [Indexed: 12/03/2022] Open
Abstract
While frontotemporal dementia (frontotemporal dementia) has been considered a neurodegenerative disease that starts in mid-life or later, it is now clearly established that cortical and subcortical volume loss is observed more than a decade prior to symptom onset and progresses with aging. To test the hypothesis that genetic mutations causing frontotemporal dementia have neurodevelopmental consequences, we have examined the youngest adults in the GENFI cohort of pre-symptomatic frontotemporal dementia mutation carriers who are between the ages of 19 and 30y. Structural brain differences and improved performance on some cognitive tests was found for MAPT and GRN mutation carriers relative to familial non-carriers, while smaller volumes were observed in C9orf72 repeat expansion carriers at a mean age of 26y. The detection of such early differences supports potential advantageous neurodevelopmental consequences of some frontotemporal dementia causing genetic mutations. These results have implications for design of therapeutic interventions for frontotemporal dementia. Future studies at younger ages are needed to identify specific early pathophysiologic or compensatory processes in the neurodevelopmental period.
Collapse
Affiliation(s)
- Elizabeth Finger
- Department of Clinical Neurological Sciences, University of Western Ontario, London, ON, Canada
| | - Rubina Malik
- Schulich School of Medicine & Dentistry, Graduate Program in Neuroscience, University of Western Ontario, London, Ontario, Canada
| | - Martina Bocchetta
- Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK
| | - Kristy Coleman
- Department of Clinical Neurological Sciences, University of Western Ontario, London, ON, Canada
| | - Caroline Graff
- Karolinska Institutet, Department NVS, Division of Neurogeriatrics, Stockholm, Sweden
- Unit for Hereditary Dementia, Theme Aging, Karolinska University Hospital-Solna Stockholm Sweden
| | - Barbara Borroni
- Centre for Neurodegenerative Disorders, Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
| | - Mario Masellis
- Campbell Cognitive Neurology Research Unit, Sunnybrook Research Institute, Toronto, ON, Canada
| | - Robert Laforce
- Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques, CHU de Québec, Faculté de Médecine, Université Laval, Québec, Canada
| | - Caroline V Greaves
- Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK
| | - Lucy L Russell
- Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK
| | - Rhian S Convery
- Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK
| | - Arabella Bouzigues
- Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK
| | - David M Cash
- Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK
| | - Markus Otto
- Department of Neurology, University Hospital Ulm, Ulm, Germany
| | - Matthis Synofzik
- Division Translational Genomics of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research (HIH), University of Tübingen, Tübingen, Germany
- German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany
| | - James B Rowe
- Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust and Medical Research Council Cognition and brain Sciences Unit, University of Cambridge, Cambridge, UK
| | - Daniela Galimberti
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy
| | | | - Robert Bartha
- Department of Medical Biophysics, The University of Western Ontario, London, Ontario, Canada
- Centre for Functional and Metabolic Mapping, Robarts Research Institute, The University of Western Ontario, London, Ontario, Canada
| | - Christen Shoesmith
- Department of Clinical Neurological Sciences, University of Western Ontario, London, ON, Canada
| | - Maria Carmela Tartaglia
- Toronto Western Hospital, Tanz Centre for Research in Neurodegenerative Disease, Toronto, ON, Canada
| | - John C van Swieten
- Department of Neurology and Alzheimer center, Erasmus Medical Center Rotterdam, the Netherlands
| | - Harro Seelaar
- Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy
| | - Lize C Jiskoo
- Department of Neurology and Alzheimer center, Erasmus Medical Center Rotterdam, the Netherlands
| | - Sandro Sorbi
- Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy
| | - Chris R Butler
- Department of Clinical Neurology, University of Oxford, Oxford, UK
| | - Alexander Gerhard
- Division of Neuroscience and Experimental Psychology, Wolfson Molecular Imaging Centre, University of Manchester, Manchester, UK
- Departments of Geriatric Medicine and Nuclear Medicine, University of Duisburg-Essen, Germany
| | - Raquel Sanchez-Valle
- Neurology Department, Hospital Clinic, Institut d'Investigacions Biomèdiques, Barcelona, Spain
| | | | - Fermin Moreno
- Hospital Universitario Donostia, San Sebastian, Spain
| | - Rik Vandenberghe
- Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium
| | - Isabelle Le Ber
- Sorbonne Université, Paris Brain Institute - Institut du Cerveau - ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France
- Centre de référence des démences rares ou précoces, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France
- Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France
| | - Johannes Levin
- Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität, Munich; German Center for Neurodegenerative Diseases (DZNE), Munich; Munich Cluster of Systems Neurology, Munich, Germany
| | - Florence Pasquier
- Univ Lille, Lille, France
- Inserm 1172, Lille, France
- CHU, CNR-MAJ, Labex Distalz, LiCEND, Lille, France
| | - Isabel Santana
- Neurology Department, Centro Hospitalar e Universitário de Coimbra, Portugal
| | - Jonathan D Rohrer
- Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK
| | - Simon Ducharme
- Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada
| | | |
Collapse
|
4
|
McKenna MC, Lope J, Tan EL, Bede P. Pre-symptomatic radiological changes in frontotemporal dementia: propagation characteristics, predictive value and implications for clinical trials. Brain Imaging Behav 2022; 16:2755-2767. [PMID: 35920960 DOI: 10.1007/s11682-022-00711-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/19/2022] [Indexed: 11/25/2022]
Abstract
Computational imaging and quantitative biomarkers offer invaluable insights in the pre-symptomatic phase of neurodegenerative conditions several years before clinical manifestation. In recent years, there has been a focused effort to characterize pre-symptomatic cerebral changes in familial frontotemporal dementias using computational imaging. Accordingly, a systematic literature review was conducted of original articles investigating pre-symptomatic imaging changes in frontotemporal dementia focusing on study design, imaging modalities, data interpretation, control cohorts and key findings. The review is limited to the most common genotypes: chromosome 9 open reading frame 72 (C9orf72), progranulin (GRN), or microtubule-associated protein tau (MAPT) genotypes. Sixty-eight studies were identified with a median sample size of 15 (3-141) per genotype. Only a minority of studies were longitudinal (28%; 19/68) with a median follow-up of 2 (1-8) years. MRI (97%; 66/68) was the most common imaging modality, and primarily grey matter analyses were conducted (75%; 19/68). Some studies used multimodal analyses 44% (30/68). Genotype-associated imaging signatures are presented, innovative study designs are highlighted, common methodological shortcomings are discussed and lessons for future studies are outlined. Emerging academic observations have potential clinical implications for expediting the diagnosis, tracking disease progression and optimising the timing of pharmaceutical trials.
Collapse
Affiliation(s)
- Mary Clare McKenna
- Computational Neuroimaging Group, Biomedical Sciences Institute, Trinity College Dublin, Room 5.43, Pearse Street, Dublin 2, Ireland.,Department of Neurology, St James's Hospital, Dublin, Ireland
| | - Jasmin Lope
- Computational Neuroimaging Group, Biomedical Sciences Institute, Trinity College Dublin, Room 5.43, Pearse Street, Dublin 2, Ireland
| | - Ee Ling Tan
- Computational Neuroimaging Group, Biomedical Sciences Institute, Trinity College Dublin, Room 5.43, Pearse Street, Dublin 2, Ireland
| | - Peter Bede
- Computational Neuroimaging Group, Biomedical Sciences Institute, Trinity College Dublin, Room 5.43, Pearse Street, Dublin 2, Ireland. .,Department of Neurology, St James's Hospital, Dublin, Ireland.
| |
Collapse
|
5
|
Ryan B, O’Mara Baker A, Ilse C, Brickell KL, Kersten HM, Williams JM, Addis DR, Tippett LJ, Curtis MA. The New Zealand Genetic Frontotemporal Dementia Study (FTDGeNZ): a longitudinal study of pre-symptomatic biomarkers. J R Soc N Z 2022. [DOI: 10.1080/03036758.2022.2101483] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
Affiliation(s)
- Brigid Ryan
- Department of Anatomy and Medical Imaging, University of Auckland, Auckland, New Zealand
- Centre for Brain Research, University of Auckland, Auckland, New Zealand
- Brain Research New Zealand, Rangahau Roro Aotearoa, New Zealand
| | - Ashleigh O’Mara Baker
- Centre for Brain Research, University of Auckland, Auckland, New Zealand
- School of Psychology, University of Auckland, Auckland, New Zealand
- Brain Research New Zealand, Rangahau Roro Aotearoa, New Zealand
| | - Christina Ilse
- Centre for Brain Research, University of Auckland, Auckland, New Zealand
- Brain Research New Zealand, Rangahau Roro Aotearoa, New Zealand
| | - Kiri L. Brickell
- Centre for Brain Research, University of Auckland, Auckland, New Zealand
- Brain Research New Zealand, Rangahau Roro Aotearoa, New Zealand
| | - Hannah M. Kersten
- School of Optometry and Vision Science, University of Auckland, Auckland, New Zealand
| | - Joanna M. Williams
- Department of Anatomy, University of Otago, Dunedin, New Zealand
- Brain Health Research Centre, University of Otago, Dunedin, New Zealand
- Brain Research New Zealand, Rangahau Roro Aotearoa, New Zealand
| | - Donna Rose Addis
- School of Psychology, University of Auckland, Auckland, New Zealand
- Rotman Research Institute, Baycrest Health Sciences, Toronto, Canada
- Department of Psychology, University of Toronto, Toronto, Canada
| | - Lynette J. Tippett
- Centre for Brain Research, University of Auckland, Auckland, New Zealand
- School of Psychology, University of Auckland, Auckland, New Zealand
- Brain Research New Zealand, Rangahau Roro Aotearoa, New Zealand
| | - Maurice A. Curtis
- Department of Anatomy and Medical Imaging, University of Auckland, Auckland, New Zealand
- Centre for Brain Research, University of Auckland, Auckland, New Zealand
- Brain Research New Zealand, Rangahau Roro Aotearoa, New Zealand
| |
Collapse
|
6
|
Nelson A, Russell LL, Peakman G, Convery RS, Bouzigues A, Greaves CV, Bocchetta M, Cash DM, van Swieten JC, Jiskoot L, Moreno F, Sanchez-Valle R, Laforce R, Graff C, Masellis M, Tartaglia MC, Rowe JB, Borroni B, Finger E, Synofzik M, Galimberti D, Vandenberghe R, de Mendonça A, Butler CR, Gerhard A, Ducharme S, Le Ber I, Santana I, Pasquier F, Levin J, Otto M, Sorbi S, Rohrer JD, Almeida MR, Anderl‐Straub S, Andersson C, Antonell A, Archetti S, Arighi A, Balasa M, Barandiaran M, Bargalló N, Bartha R, Bender B, Benussi A, Bertoux M, Bertrand A, Bessi V, Black S, Bocchetta M, Borrego‐Ecija S, Bras J, Brice A, Bruffaerts R, Camuzat A, Cañada M, Cantoni V, Caroppo P, Cash D, Castelo‐Branco M, Colliot O, Cope T, Deramecourt V, Arriba M, Di Fede G, Díez A, Duro D, Fenoglio C, Ferrari C, Ferreira CB, Fox N, Freedman M, Fumagalli G, Funkiewiez A, Gabilondo A, Gasparotti R, Gauthier S, Gazzina S, Giaccone G, Gorostidi A, Greaves C, Guerreiro R, Heller C, Hoegen T, Indakoetxea B, Jelic V, Karnath H, Keren R, Kuchcinski G, Langheinrich T, Lebouvier T, Leitão MJ, Lladó A, Lombardi G, Loosli S, Maruta C, Mead S, Meeter L, Miltenberger G, Minkelen R, Mitchell S, Moore K, Nacmias B, Nelson A, Öijerstedt L, Olives J, Ourselin S, Padovani A, Panman J, Papma JM, Pijnenburg Y, Polito C, Premi E, Prioni S, Prix C, Rademakers R, Redaelli V, Rinaldi D, Rittman T, Rogaeva E, Rollin A, Rosa‐Neto P, Rossi G, Rossor M, Santiago B, Saracino D, Sayah S, Scarpini E, Schönecker S, Seelaar H, Semler E, Shafei R, Shoesmith C, Swift I, Tábuas‐Pereira M, Tainta M, Taipa R, Tang‐Wai D, Thomas DL, Thompson P, Thonberg H, Timberlake C, Tiraboschi P, Todd E, Van Damme P, Vandenbulcke M, Veldsman M, Verdelho A, Villanua J, Warren J, Wilke C, Wlasich E, Zetterberg H, Zulaica M. The CBI-R detects early behavioural impairment in genetic frontotemporal dementia. Ann Clin Transl Neurol 2022; 9:644-658. [PMID: 35950369 PMCID: PMC9082390 DOI: 10.1002/acn3.51544] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2022] [Revised: 02/23/2022] [Accepted: 02/25/2022] [Indexed: 11/17/2022] Open
Abstract
INTRODUCTION Behavioural dysfunction is a key feature of genetic frontotemporal dementia (FTD) but validated clinical scales measuring behaviour are lacking at present. METHODS We assessed behaviour using the revised version of the Cambridge Behavioural Inventory (CBI-R) in 733 participants from the Genetic FTD Initiative study: 466 mutation carriers (195 C9orf72, 76 MAPT, 195 GRN) and 267 non-mutation carriers (controls). All mutation carriers were stratified according to their global CDR plus NACC FTLD score into three groups: asymptomatic (CDR = 0), prodromal (CDR = 0.5) and symptomatic (CDR = 1+). Mixed-effects models adjusted for age, education, sex and family clustering were used to compare between the groups. Neuroanatomical correlates of the individual domains were assessed within each genetic group. RESULTS CBI-R total scores were significantly higher in all CDR 1+ mutation carrier groups compared with controls [C9orf72 mean 70.5 (standard deviation 27.8), GRN 56.2 (33.5), MAPT 62.1 (36.9)] as well as their respective CDR 0.5 groups [C9orf72 13.5 (14.4), GRN 13.3 (13.5), MAPT 9.4 (10.4)] and CDR 0 groups [C9orf72 6.0 (7.9), GRN 3.6 (6.0), MAPT 8.5 (13.3)]. The C9orf72 and GRN 0.5 groups scored significantly higher than the controls. The greatest impairment was seen in the Motivation domain for the C9orf72 and GRN symptomatic groups, whilst in the symptomatic MAPTgroup, the highest-scoring domains were Stereotypic and Motor Behaviours and Memory and Orientation. Neural correlates of each CBI-R domain largely overlapped across the different mutation carrier groups. CONCLUSIONS The CBI-R detects early behavioural change in genetic FTD, suggesting that it could be a useful measure within future clinical trials.
Collapse
Affiliation(s)
- Annabel Nelson
- Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.,Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK
| | - Lucy L Russell
- Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK
| | - Georgia Peakman
- Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK
| | - Rhian S Convery
- Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK
| | - Arabella Bouzigues
- Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK
| | - Caroline V Greaves
- Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK
| | - Martina Bocchetta
- Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK
| | - David M Cash
- Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK
| | | | - Lize Jiskoot
- Department of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands
| | - Fermin Moreno
- Cognitive Disorders Unit, Department of Neurology, Donostia Universitary Hospital, San Sebastian, Spain.,Neuroscience Area, Biodonostia Health Research Institute, San Sebastian, Gipuzkoa, Spain
| | - Raquel Sanchez-Valle
- Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Institut d'Investigacións Biomèdiques August Pi I Sunyer, University of Barcelona, Barcelona, Spain
| | - Robert Laforce
- Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques, CHU de Québec, and Faculté de Médecine, Université Laval, Québec, Canada
| | - Caroline Graff
- Center for Alzheimer Research, Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Bioclinicum, Karolinska Institutet, Solna, Sweden.,Unit for Hereditary Dementias, Theme Aging, Karolinska University Hospital, Solna, Sweden
| | - Mario Masellis
- Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Toronto, Canada
| | - Maria Carmela Tartaglia
- Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada
| | - James B Rowe
- Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
| | - Barbara Borroni
- Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
| | - Elizabeth Finger
- Department of Clinical Neurological Sciences, University of Western Ontario, London, Ontario, Canada
| | - Matthis Synofzik
- Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany.,Center for Neurodegenerative Diseases (DZNE, Tübingen, Germany
| | - Daniela Galimberti
- Fondazione Ca' Granda, IRCCS Ospedale Policlinico, Milan, Italy.,University of Milan, Centro Dino Ferrari, Milan, Italy
| | - Rik Vandenberghe
- Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium.,Neurology Service, University Hospitals Leuven, Leuven, Belgium.,Leuven Brain Institute, KU Leuven, Leuven, Belgium
| | | | - Chris R Butler
- Nuffield Department of Clinical Neurosciences, Medical Sciences Division, University of Oxford, Oxford, UK.,Department of Brain Sciences, Imperial College London, London, UK
| | - Alexander Gerhard
- Division of Neuroscience and Experimental Psychology, Wolfson Molecular Imaging Centre, University of Manchester, Manchester, UK.,Departments of Geriatric Medicine and Nuclear Medicine, University of Duisburg-Essen, Duisburg, Germany
| | - Simon Ducharme
- Department of Psychiatry, McGill University Health Centre, McGill University, Montreal, QC, Canada.,McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, QC, Canada
| | - Isabelle Le Ber
- Sorbonne Université, Paris Brain Institute - Institut du Cerveau - ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France.,Département de Neurologie, Centre de référence des démences rares ou précoces, IM2A, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France.,Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France.,Reference Network for Rare Neurological Diseases (ERN-RND), European Union
| | - Isabel Santana
- University Hospital of Coimbra (HUC), Neurology Service, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.,Center for Neuroscience and Cell Biology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal
| | - Florence Pasquier
- Univ Lille, Lille, France.,Inserm 1172, Lille, France.,CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, Lille, France
| | - Johannes Levin
- Department of Neurology, Ludwig-Maximilians Universität München, Munich, Germany.,German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.,Munich Cluster of Systems Neurology (SyNergy), Munich, Germany
| | - Markus Otto
- Department of Neurology, University of Ulm, Ulm, Germany
| | - Sandro Sorbi
- Department of Neurofarba, University of Florence, Florence, Italy.,IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy
| | - Jonathan D Rohrer
- Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
McKenna MC, Murad A, Huynh W, Lope J, Bede P. The changing landscape of neuroimaging in frontotemporal lobar degeneration: from group-level observations to single-subject data interpretation. Expert Rev Neurother 2022; 22:179-207. [PMID: 35227146 DOI: 10.1080/14737175.2022.2048648] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
INTRODUCTION While the imaging signatures of frontotemporal lobar degeneration (FTLD) phenotypes and genotypes are well-characterised based on group-level descriptive analyses, the meaningful interpretation of single MRI scans remains challenging. Single-subject MRI classification frameworks rely on complex computational models and large training datasets to categorise individual patients into diagnostic subgroups based on distinguishing imaging features. Reliable individual subject data interpretation is hugely important in the clinical setting to expedite the diagnosis and classify individuals into relevant prognostic categories. AREAS COVERED This article reviews (1) the neuroimaging studies that propose single-subject MRI classification strategies in symptomatic and pre-symptomatic FTLD, (2) potential practical implications and (3) the limitations of current single-subject data interpretation models. EXPERT OPINION Classification studies in FTLD have demonstrated the feasibility of categorising individual subjects into diagnostic groups based on multiparametric imaging data. Preliminary data indicate that pre-symptomatic FTLD mutation carriers may also be reliably distinguished from controls. Despite momentous advances in the field, significant further improvements are needed before these models can be developed into viable clinical applications.
Collapse
Affiliation(s)
| | - Aizuri Murad
- Computational Neuroimaging Group, Trinity College Dublin, Ireland
| | - William Huynh
- Brain and Mind Centre, University of Sydney, Australia
| | - Jasmin Lope
- Computational Neuroimaging Group, Trinity College Dublin, Ireland
| | - Peter Bede
- Computational Neuroimaging Group, Trinity College Dublin, Ireland.,Pitié-Salpêtrière University Hospital, Sorbonne University, France
| |
Collapse
|
8
|
A comparison of automated atrophy measures across the frontotemporal dementia spectrum: Implications for trials. NEUROIMAGE-CLINICAL 2021; 32:102842. [PMID: 34626889 PMCID: PMC8503665 DOI: 10.1016/j.nicl.2021.102842] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/19/2021] [Revised: 08/13/2021] [Accepted: 09/23/2021] [Indexed: 11/22/2022]
Abstract
Background Frontotemporal dementia (FTD) is a common cause of young onset dementia, and whilst there are currently no treatments, there are several promising candidates in development and early phase trials. Comprehensive investigations of neuroimaging markers of disease progression across the full spectrum of FTD disorders are lacking and urgently needed to facilitate these trials. Objective To investigate the comparative performance of multiple automated segmentation and registration pipelines used to quantify longitudinal whole-brain atrophy across the clinical, genetic and pathological subgroups of FTD, in order to inform upcoming trials about suitable neuroimaging-based endpoints. Methods Seventeen fully automated techniques for extracting whole-brain atrophy measures were applied and directly compared in a cohort of 226 participants who had undergone longitudinal structural 3D T1-weighted imaging. Clinical diagnoses were behavioural variant FTD (n = 56) and primary progressive aphasia (PPA, n = 104), comprising semantic variant PPA (n = 38), non-fluent variant PPA (n = 42), logopenic variant PPA (n = 18), and PPA-not otherwise specified (n = 6). 49 of these patients had either a known pathogenic mutation or postmortem confirmation of their underlying pathology. 66 healthy controls were included for comparison. Sample size estimates to detect a 30% reduction in atrophy (80% power; 0.05 significance) were computed to explore the relative feasibility of these brain measures as surrogate markers of disease progression and their ability to detect putative disease-modifying treatment effects. Results Multiple automated techniques showed great promise, detecting significantly increased rates of whole-brain atrophy (p<0.001) and requiring sample sizes of substantially less than 100 patients per treatment arm. Across the different FTD subgroups, direct measures of volume change consistently outperformed their indirect counterparts, irrespective of the initial segmentation quality. Significant differences in performance were found between both techniques and patient subgroups, highlighting the importance of informed biomarker choice based on the patient population of interest. Conclusion This work expands current knowledge and builds on the limited longitudinal investigations currently available in FTD, as well as providing valuable information about the potential of fully automated neuroimaging biomarkers for sporadic and genetic FTD trials.
Collapse
|
9
|
Feis RA, van der Grond J, Bouts MJRJ, Panman JL, Poos JM, Schouten TM, de Vos F, Jiskoot LC, Dopper EGP, van Buchem MA, van Swieten JC, Rombouts SARB. Classification using fractional anisotropy predicts conversion in genetic frontotemporal dementia, a proof of concept. Brain Commun 2021; 2:fcaa079. [PMID: 33543126 PMCID: PMC7846185 DOI: 10.1093/braincomms/fcaa079] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2019] [Revised: 04/29/2020] [Accepted: 05/11/2020] [Indexed: 11/14/2022] Open
Abstract
Frontotemporal dementia is a highly heritable and devastating neurodegenerative disease. About 10–20% of all frontotemporal dementia is caused by known pathogenic mutations, but a reliable tool to predict clinical conversion in mutation carriers is lacking. In this retrospective proof-of-concept case-control study, we investigate whether MRI-based and cognition-based classifiers can predict which mutation carriers from genetic frontotemporal dementia families will develop symptoms (‘convert’) within 4 years. From genetic frontotemporal dementia families, we included 42 presymptomatic frontotemporal dementia mutation carriers. We acquired anatomical, diffusion-weighted imaging, and resting-state functional MRI, as well as neuropsychological data. After 4 years, seven mutation carriers had converted to frontotemporal dementia (‘converters’), while 35 had not (‘non-converters’). We trained regularized logistic regression models on baseline MRI and cognitive data to predict conversion to frontotemporal dementia within 4 years, and quantified prediction performance using area under the receiver operating characteristic curves. The prediction model based on fractional anisotropy, with highest contribution of the forceps minor, predicted conversion to frontotemporal dementia beyond chance level (0.81 area under the curve, family-wise error corrected P = 0.025 versus chance level). Other MRI-based and cognitive features did not outperform chance level. Even in a small sample, fractional anisotropy predicted conversion in presymptomatic frontotemporal dementia mutation carriers beyond chance level. After validation in larger data sets, conversion prediction in genetic frontotemporal dementia may facilitate early recruitment into clinical trials.
Collapse
Affiliation(s)
- Rogier A Feis
- Department of Radiology, Leiden University Medical Centre, 2333 ZA, Leiden, the Netherlands.,Leiden Institute for Brain and Cognition, Leiden University, 2333 ZA, Leiden, the Netherlands.,Institute of Psychology, Leiden University, 2333 AK, Leiden, the Netherlands
| | - Jeroen van der Grond
- Department of Radiology, Leiden University Medical Centre, 2333 ZA, Leiden, the Netherlands
| | - Mark J R J Bouts
- Department of Radiology, Leiden University Medical Centre, 2333 ZA, Leiden, the Netherlands.,Leiden Institute for Brain and Cognition, Leiden University, 2333 ZA, Leiden, the Netherlands.,Institute of Psychology, Leiden University, 2333 AK, Leiden, the Netherlands
| | - Jessica L Panman
- Department of Radiology, Leiden University Medical Centre, 2333 ZA, Leiden, the Netherlands.,Department of Neurology, Erasmus Medical Centre, 3015 GD, Rotterdam, the Netherlands
| | - Jackie M Poos
- Department of Radiology, Leiden University Medical Centre, 2333 ZA, Leiden, the Netherlands.,Department of Neurology, Erasmus Medical Centre, 3015 GD, Rotterdam, the Netherlands
| | - Tijn M Schouten
- Department of Radiology, Leiden University Medical Centre, 2333 ZA, Leiden, the Netherlands.,Leiden Institute for Brain and Cognition, Leiden University, 2333 ZA, Leiden, the Netherlands.,Institute of Psychology, Leiden University, 2333 AK, Leiden, the Netherlands
| | - Frank de Vos
- Department of Radiology, Leiden University Medical Centre, 2333 ZA, Leiden, the Netherlands.,Leiden Institute for Brain and Cognition, Leiden University, 2333 ZA, Leiden, the Netherlands.,Institute of Psychology, Leiden University, 2333 AK, Leiden, the Netherlands
| | - Lize C Jiskoot
- Department of Radiology, Leiden University Medical Centre, 2333 ZA, Leiden, the Netherlands.,Department of Neurology, Erasmus Medical Centre, 3015 GD, Rotterdam, the Netherlands.,Dementia Research Centre, University College London, London, WC1N 3AR, UK
| | - Elise G P Dopper
- Department of Radiology, Leiden University Medical Centre, 2333 ZA, Leiden, the Netherlands.,Department of Neurology, Erasmus Medical Centre, 3015 GD, Rotterdam, the Netherlands
| | - Mark A van Buchem
- Department of Radiology, Leiden University Medical Centre, 2333 ZA, Leiden, the Netherlands.,Leiden Institute for Brain and Cognition, Leiden University, 2333 ZA, Leiden, the Netherlands
| | - John C van Swieten
- Department of Neurology, Erasmus Medical Centre, 3015 GD, Rotterdam, the Netherlands
| | - Serge A R B Rombouts
- Department of Radiology, Leiden University Medical Centre, 2333 ZA, Leiden, the Netherlands.,Leiden Institute for Brain and Cognition, Leiden University, 2333 ZA, Leiden, the Netherlands.,Institute of Psychology, Leiden University, 2333 AK, Leiden, the Netherlands
| |
Collapse
|
10
|
Borrego-Écija S, Sala-Llonch R, van Swieten J, Borroni B, Moreno F, Masellis M, Tartaglia C, Graff C, Galimberti D, Laforce R, Rowe JB, Finger E, Vandenberghe R, Tagliavini F, de Mendonça A, Santana I, Synofzik M, Ducharme S, Levin J, Danek A, Gerhard A, Otto M, Butler C, Frisoni G, Sorbi S, Heller C, Bocchetta M, Cash DM, Convery RS, Moore KM, Rohrer JD, Sanchez-Valle R. Disease-related cortical thinning in presymptomatic granulin mutation carriers. NEUROIMAGE-CLINICAL 2020; 29:102540. [PMID: 33418170 PMCID: PMC7804836 DOI: 10.1016/j.nicl.2020.102540] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/23/2020] [Revised: 12/14/2020] [Accepted: 12/15/2020] [Indexed: 12/12/2022]
Abstract
No differences in cortical thickness were found between presymptomatic GRN mutation carriers and non-carriers at the group-wise comparison. Presymptomatic GRN mutations carriers present distinct age-related CTh loss in frontal areas. We do not fount influence of the TMEM106B genotype in the age-related CTh of GRN carriers.
Mutations in the granulin gene (GRN) cause familial frontotemporal dementia. Understanding the structural brain changes in presymptomatic GRN carriers would enforce the use of neuroimaging biomarkers for early diagnosis and monitoring. We studied 100 presymptomatic GRN mutation carriers and 94 noncarriers from the Genetic Frontotemporal dementia initiative (GENFI), with MRI structural images. We analyzed 3T MRI structural images using the FreeSurfer pipeline to calculate the whole brain cortical thickness (CTh) for each subject. We also perform a vertex-wise general linear model to assess differences between groups in the relationship between CTh and diverse covariables as gender, age, the estimated years to onset and education. We also explored differences according to TMEM106B genotype, a possible disease modifier. Whole brain CTh did not differ between carriers and noncarriers. Both groups showed age-related cortical thinning. The group-by-age interaction analysis showed that this age-related cortical thinning was significantly greater in GRN carriers in the left superior frontal cortex. TMEM106B did not significantly influence the age-related cortical thinning. Our results validate and expand previous findings suggesting an increased CTh loss associated with age and estimated proximity to symptoms onset in GRN carriers, even before the disease onset.
Collapse
Affiliation(s)
- Sergi Borrego-Écija
- Alzheimer's disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi I Sunyer, Barcelona, Spain
| | - Roser Sala-Llonch
- Departament de Biomedicina, Institute of Neuroscience, University of Barcelona, Institute of Biomedical Research August Pi i Sunyer (IDIBAPS), Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Spain
| | - John van Swieten
- Department of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands
| | - Barbara Borroni
- Centre for Neurodegenerative Disorders, Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
| | - Fermín Moreno
- Cognitive Disorders Unit, Department of Neurology, Donostia University Hospital, San Sebastian, Gipuzkoa, Spain
| | - Mario Masellis
- LC Campbell Cognitive Neurology Research Unit, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada
| | - Carmela Tartaglia
- Toronto Western Hospital, Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada
| | - Caroline Graff
- Department of Geriatric Medicine, Karolinska University Hospital-Huddinge, Stockholm, Sweden
| | - Daniela Galimberti
- Biomedical, Surgical and Dental Sciences, University of Milan, Centro Dino Ferrari, Milan, Italy; Fondazione IRCCS Ca' Granda, Ospedale Policlinico, Neurodegenerative Diseases Unit, Milan, Italy
| | - Robert Laforce
- Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques, Université Laval, Québec, Canada
| | - James B Rowe
- Department of Clinical Neurosciences and Medical Research Council, Cognition and Brain Sciences Unit, University of Cambridge, Cambridge, United Kingdom
| | - Elizabeth Finger
- Department of Clinical Neurological Sciences, University of Western Ontario, London, Ontario, Canada
| | - Rik Vandenberghe
- Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium
| | - Fabrizio Tagliavini
- Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Neurologica Carlo Besta, Milano, Italy
| | | | - Isabel Santana
- Faculty of Medicine, University of Coimbra, Coimbra, Portugal
| | - Matthis Synofzik
- Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany; German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany
| | - Simon Ducharme
- Department of Psychiatry, McGill University Health Centre, McGill University, Montreal, Québec, Canada; McConnell Brain Imaging Centre, Montreal Neurological Institut, McGill University, Montreal, Québec, Canada
| | - Johannes Levin
- Department of Neurology, Ludwig-Maximilians-University, Munich, Germany; German Center for Neurodegenerative Diseases (DZNE), Site Munich, Munich, Germany; SyNergy,Munich Cluster for Systems Neurology, Munich, Germany
| | - Adrian Danek
- Department of Neurology, Ludwig-Maximilians-University, Munich, Germany
| | - Alex Gerhard
- Faculty of Medical and Human Sciences, Institute of Brain, Behaviour and Mental Health, University of Manchester, Manchester, UK
| | - Markus Otto
- Department of Neurology, University of Ulm, Ulm, Germany
| | - Chris Butler
- Department of Clinical Neurology, University of Oxford, Oxford, United Kingdom
| | - Giovanni Frisoni
- Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy; Memory Clinic LANVIE-Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Geneva, Switzerland
| | - Sandro Sorbi
- Department of Neuroscience, Psychology, Drug Research, and Child Health, University of Florence, Florence, Italy; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Don Carlo Gnocchi, Florence, Italy
| | - Carolin Heller
- Dementia Research Centre, Department of Neurodegenerative Disease, Queen Square UCL Institute of Neurology, London, UK
| | - Martina Bocchetta
- Dementia Research Centre, Department of Neurodegenerative Disease, Queen Square UCL Institute of Neurology, London, UK
| | - David M Cash
- Dementia Research Centre, Department of Neurodegenerative Disease, Queen Square UCL Institute of Neurology, London, UK
| | - Rhian S Convery
- Dementia Research Centre, Department of Neurodegenerative Disease, Queen Square UCL Institute of Neurology, London, UK
| | - Katrina M Moore
- Dementia Research Centre, Department of Neurodegenerative Disease, Queen Square UCL Institute of Neurology, London, UK
| | - Jonathan D Rohrer
- Dementia Research Centre, Department of Neurodegenerative Disease, Queen Square UCL Institute of Neurology, London, UK
| | - Raquel Sanchez-Valle
- Alzheimer's disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi I Sunyer, Barcelona, Spain; Departament de Biomedicina, Institute of Neuroscience, University of Barcelona, Institute of Biomedical Research August Pi i Sunyer (IDIBAPS), Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Spain.
| | | |
Collapse
|
11
|
Chipika RH, Siah WF, McKenna MC, Li Hi Shing S, Hardiman O, Bede P. The presymptomatic phase of amyotrophic lateral sclerosis: are we merely scratching the surface? J Neurol 2020; 268:4607-4629. [PMID: 33130950 DOI: 10.1007/s00415-020-10289-5] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2020] [Revised: 10/18/2020] [Accepted: 10/20/2020] [Indexed: 02/06/2023]
Abstract
Presymptomatic studies in ALS have consistently captured considerable disease burden long before symptom manifestation and contributed important academic insights. With the emergence of genotype-specific therapies, however, there is a pressing need to address practical objectives such as the estimation of age of symptom onset, phenotypic prediction, informing the optimal timing of pharmacological intervention, and identifying a core panel of biomarkers which may detect response to therapy. Existing presymptomatic studies in ALS have adopted striking different study designs, relied on a variety of control groups, used divergent imaging and electrophysiology methods, and focused on different genotypes and demographic groups. We have performed a systematic review of existing presymptomatic studies in ALS to identify common themes, stereotyped shortcomings, and key learning points for future studies. Existing presymptomatic studies in ALS often suffer from sample size limitations, lack of disease controls and rarely follow their cohort until symptom manifestation. As the characterisation of presymptomatic processes in ALS serves a multitude of academic and clinical purposes, the careful review of existing studies offers important lessons for future initiatives.
Collapse
Affiliation(s)
- Rangariroyashe H Chipika
- Computational Neuroimaging Group (CNG), Biomedical Sciences Institute, Trinity College Dublin, Pearse Street, Dublin, Ireland
| | - We Fong Siah
- Computational Neuroimaging Group (CNG), Biomedical Sciences Institute, Trinity College Dublin, Pearse Street, Dublin, Ireland
| | - Mary Clare McKenna
- Computational Neuroimaging Group (CNG), Biomedical Sciences Institute, Trinity College Dublin, Pearse Street, Dublin, Ireland
| | - Stacey Li Hi Shing
- Computational Neuroimaging Group (CNG), Biomedical Sciences Institute, Trinity College Dublin, Pearse Street, Dublin, Ireland
| | - Orla Hardiman
- Computational Neuroimaging Group (CNG), Biomedical Sciences Institute, Trinity College Dublin, Pearse Street, Dublin, Ireland
| | - Peter Bede
- Computational Neuroimaging Group (CNG), Biomedical Sciences Institute, Trinity College Dublin, Pearse Street, Dublin, Ireland.
| |
Collapse
|
12
|
Häkkinen S, Chu SA, Lee SE. Neuroimaging in genetic frontotemporal dementia and amyotrophic lateral sclerosis. Neurobiol Dis 2020; 145:105063. [PMID: 32890771 DOI: 10.1016/j.nbd.2020.105063] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2020] [Revised: 07/30/2020] [Accepted: 08/26/2020] [Indexed: 02/06/2023] Open
Abstract
Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) have a strong clinical, genetic and pathological overlap. This review focuses on the current understanding of structural, functional and molecular neuroimaging signatures of genetic FTD and ALS. We overview quantitative neuroimaging studies on the most common genes associated with FTD (MAPT, GRN), ALS (SOD1), and both (C9orf72), and summarize visual observations of images reported in the rarer genes (CHMP2B, TARDBP, FUS, OPTN, VCP, UBQLN2, SQSTM1, TREM2, CHCHD10, TBK1).
Collapse
Affiliation(s)
- Suvi Häkkinen
- Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
| | - Stephanie A Chu
- Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
| | - Suzee E Lee
- Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.
| |
Collapse
|
13
|
Suppa A, Fabbrini A, Guerra A, Petsas N, Asci F, Di Stasio F, Trebbastoni A, Vasselli F, De Lena C, Pantano P, Berardelli A. Altered speech-related cortical network in frontotemporal dementia. Brain Stimul 2020; 13:765-773. [PMID: 32289706 DOI: 10.1016/j.brs.2020.02.029] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2019] [Revised: 01/08/2020] [Accepted: 02/24/2020] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND In healthy subjects (HS), transcranial magnetic stimulation (TMS) demonstrated an increase in motor-evoked potential (MEP) amplitudes during specific linguistic tasks. This finding indicates functional connections between speech-related cortical areas and the dominant primary motor cortex (M1). OBJECTIVE To investigate M1 function with TMS and the speech-related cortical network with neuroimaging measures in frontotemporal dementia (FTD), including the non-fluent variant of primary progressive aphasia (nfv-PPA) and the behavioral variant of FTD (bv-FTD). METHODS M1 excitability changes during specific linguistc tasks were examined using TMS in 24 patients (15 with nfv-PPA and 9 with bv-FTD) and in 18 age-matched HS. In the same patients neuroimaging was used to assess changes in specific white matter (WM) bundles and grey matter (GM) regions involved in language processing, with diffusion tensor imaging (DTI) and voxel-based morphometry (VBM). RESULTS During the linguistic task, M1 excitability increased in HS, whereas in FTD patients it did not. M1 excitability changes were comparable in nfv-PPA and bv-FTD. DTI revealed decreased fractional anisotropy in the superior and inferior longitudinal and uncinate fasciculi. Moreover, VBM disclosed GM volume loss in the left frontal operculum though not in the parietal operculum or precentral gyrus. Furthermore, WM and GM changes were comparable in nfv-PPA and bv-FTD. There was no correlation between neurophysiological and neuroimaging changes in FTD. Atrophy in the left frontal operculum correlated with linguistic dysfunction, assessed by semantic and phonemic fluency tests. CONCLUSION We provide converging neurophysiological and neuroimaging evidence of abnormal speech-related cortical network activation in FTD.
Collapse
Affiliation(s)
- Antonio Suppa
- Department of Human Neurosciences, Sapienza University of Rome, Viale Dell'Università 30, 00185, Rome, Italy; IRCCS Neuromed, Via Atinense 18, 86077, Pozzilli, IS, Italy
| | | | - Andrea Guerra
- IRCCS Neuromed, Via Atinense 18, 86077, Pozzilli, IS, Italy
| | | | - Francesco Asci
- Department of Human Neurosciences, Sapienza University of Rome, Viale Dell'Università 30, 00185, Rome, Italy
| | - Flavio Di Stasio
- Department of Neurology, St John the Baptist Hospital, ACISMOM, 00148, Rome, Italy
| | - Alessandro Trebbastoni
- Department of Human Neurosciences, Sapienza University of Rome, Viale Dell'Università 30, 00185, Rome, Italy
| | - Federica Vasselli
- Department of Human Neurosciences, Sapienza University of Rome, Viale Dell'Università 30, 00185, Rome, Italy
| | - Carlo De Lena
- Department of Human Neurosciences, Sapienza University of Rome, Viale Dell'Università 30, 00185, Rome, Italy
| | - Patrizia Pantano
- Department of Human Neurosciences, Sapienza University of Rome, Viale Dell'Università 30, 00185, Rome, Italy; IRCCS Neuromed, Via Atinense 18, 86077, Pozzilli, IS, Italy
| | - Alfredo Berardelli
- Department of Human Neurosciences, Sapienza University of Rome, Viale Dell'Università 30, 00185, Rome, Italy; IRCCS Neuromed, Via Atinense 18, 86077, Pozzilli, IS, Italy.
| |
Collapse
|
14
|
Chen Q, Boeve BF, Senjem M, Tosakulwong N, Lesnick T, Brushaber D, Dheel C, Fields J, Forsberg L, Gavrilova R, Gearhart D, Graff-Radford J, Graff-Radford N, Jack CR, Jones D, Knopman D, Kremers WK, Lapid M, Rademakers R, Ramos EM, Syrjanen J, Boxer AL, Rosen H, Wszolek ZK, Kantarci K. Trajectory of lobar atrophy in asymptomatic and symptomatic GRN mutation carriers: a longitudinal MRI study. Neurobiol Aging 2020; 88:42-50. [PMID: 31918955 PMCID: PMC7767622 DOI: 10.1016/j.neurobiolaging.2019.12.004] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2019] [Revised: 12/03/2019] [Accepted: 12/06/2019] [Indexed: 02/05/2023]
Abstract
Loss-of-function mutations in the progranulin gene (GRN) are one of the major causes of familial frontotemporal lobar degeneration. Our objective was to determine the rates and trajectories of lobar cortical atrophy from longitudinal structural magnetic resonance imaging in both asymptomatic and symptomatic GRN mutation carriers. Individuals in this study were from the ADRC and LEFFTDS studies at the Mayo Clinic. We identified 13 GRN mutation carriers (8 asymptomatic, 5 symptomatic) and noncarriers (n = 10) who had at least 2 serial T1-weighted structural magnetic resonance images and were followed annually with a median of 3 years (range 1.0-9.8 years). Longitudinal changes in lobar cortical volume were analyzed using the tensor-based morphometry with symmetric normalization (TBM-SyN) algorithm. Linear mixed-effect models were used to model cortical volume change over time among 3 groups. The annual rates of frontal (p < 0.05) and parietal (p < 0.01) lobe cortical atrophy were higher in asymptomatic GRN mutation carriers than noncarriers. The symptomatic GRN mutation carriers also had increased rates of atrophy in the frontal (p < 0.01) and parietal lobe (p < 0.01) cortices than noncarriers. In addition, greater rates of cortical atrophy were observed in the temporal lobe cortices of symptomatic GRN mutation carriers than noncarriers (p < 0.001). We found that a decline in frontal and parietal lobar cortical volume occurs in asymptomatic GRN mutation carriers and continues in the symptomatic GRN mutation carriers, whereas an increased rate of temporal lobe cortical atrophy is observed only in symptomatic GRN mutation carriers. This sequential pattern of cortical involvement in GRN mutation carriers has important implications for using imaging biomarkers of neurodegeneration as an outcome measure in potential treatment trials involving GRN mutation carriers.
Collapse
Affiliation(s)
- Qin Chen
- Department of Neurology, West China Hospital of Sichuan University, Chengdu, Sichuan, China; Department of Radiology, Mayo Clinic, Rochester, MN, USA
| | - Bradley F Boeve
- Department of Neurology, Mayo Clinic, Rochester, MN, USA; Alzheimer's Disease Research Center, Mayo Clinic, Rochester, MN, USA
| | - Matthew Senjem
- Department of Radiology, Mayo Clinic, Rochester, MN, USA
| | | | - Timothy Lesnick
- Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA
| | - Danielle Brushaber
- Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA; Alzheimer's Disease Research Center, Mayo Clinic, Rochester, MN, USA
| | - Christina Dheel
- Department of Neurology, Mayo Clinic, Rochester, MN, USA; Alzheimer's Disease Research Center, Mayo Clinic, Rochester, MN, USA
| | - Julie Fields
- Department of Psychology and Psychiatry, Mayo Clinic, Rochester, MN, USA
| | - Leah Forsberg
- Department of Neurology, Mayo Clinic, Rochester, MN, USA; Alzheimer's Disease Research Center, Mayo Clinic, Rochester, MN, USA
| | - Ralitza Gavrilova
- Department of Clinical Genomic and Neurology, Mayo Clinic, Rochester, MN, USA
| | - Debra Gearhart
- Department of Neurology, Mayo Clinic, Rochester, MN, USA; Alzheimer's Disease Research Center, Mayo Clinic, Rochester, MN, USA
| | - Jonathan Graff-Radford
- Department of Neurology, Mayo Clinic, Rochester, MN, USA; Alzheimer's Disease Research Center, Mayo Clinic, Rochester, MN, USA
| | | | - Clifford R Jack
- Department of Radiology, Mayo Clinic, Rochester, MN, USA; Alzheimer's Disease Research Center, Mayo Clinic, Rochester, MN, USA
| | - David Jones
- Department of Neurology, Mayo Clinic, Rochester, MN, USA; Alzheimer's Disease Research Center, Mayo Clinic, Rochester, MN, USA
| | - David Knopman
- Department of Neurology, Mayo Clinic, Rochester, MN, USA; Alzheimer's Disease Research Center, Mayo Clinic, Rochester, MN, USA
| | - Walter K Kremers
- Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA
| | - Maria Lapid
- Department of Psychology and Psychiatry, Mayo Clinic, Rochester, MN, USA
| | - Rosa Rademakers
- Alzheimer's Disease Research Center, Mayo Clinic, Rochester, MN, USA; Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA
| | - Eliana Marisa Ramos
- Department of Psychiatry, David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, USA
| | - Jeremy Syrjanen
- Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA
| | - Adam L Boxer
- Memory and Aging Center, University of California San Francisco, San Francisco, CA, USA
| | - Howie Rosen
- Memory and Aging Center, University of California San Francisco, San Francisco, CA, USA
| | | | - Kejal Kantarci
- Department of Radiology, Mayo Clinic, Rochester, MN, USA; Alzheimer's Disease Research Center, Mayo Clinic, Rochester, MN, USA.
| |
Collapse
|
15
|
Chen Q, Kantarci K. Imaging Biomarkers for Neurodegeneration in Presymptomatic Familial Frontotemporal Lobar Degeneration. Front Neurol 2020; 11:80. [PMID: 32184751 PMCID: PMC7058699 DOI: 10.3389/fneur.2020.00080] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2019] [Accepted: 01/22/2020] [Indexed: 02/05/2023] Open
Abstract
Frontotemporal lobar degeneration (FTLD) is a neurodegenerative disorder characterized by behavioral changes, language abnormality, as well as executive function deficits and motor impairment. In about 30-50% of FTLD patients, an autosomal dominant pattern of inheritance was found with major mutations in the MAPT, GRN, and the C9orf72 repeat expansion. These mutations could lead to neurodegenerative pathology years before clinical symptoms onset. With potential disease-modifying treatments that are under development, non-invasive biomarkers that help determine the early brain changes in presymptomatic FTLD patients will be critical for tracking disease progression and enrolling the right participants into the clinical trials at the right time during the disease course. In recent years, there is increasing evidence that a number of imaging biomarkers show the abnormalities during the presymptomatic stage. Imaging biomarkers of presymptomatic familial FTLD may provide insight into the underlying neurodegenerative process years before symptom onset. Structural magnetic resonance imaging (MRI) has demonstrated cortical degeneration with a mutation-specific neurodegeneration pattern years before onset of clinical symptoms in presymptomatic familial FTLD mutation carriers. In addition, diffusion tensor imaging (DTI) has shown the loss of white matter microstructural integrity in the presymptomatic stage of familial FTLD. Furthermore, proton magnetic resonance spectroscopy (1H MRS), which provides a non-invasive measurement of brain biochemistry, has identified early neurochemical abnormalities in presymptomatic MAPT mutation carriers. Positron emission tomography (PET) imaging with [18F]-fluorodeoxyglucose (FDG) has demonstrated the glucose hypometabolism in the presymptomatic stage of familial FTLD. Also, a novel PET ligand, 18F-AV-1451, has been used in this group to evaluate tau deposition in the brain. Promising imaging biomarkers for presymptomatic familial FTLD have been identified and assessed for specificity and sensitivity for accurate prediction of symptom onset and tracking disease progression during the presymptomatic stage when clinical measures are not useful. Furthermore, identifying imaging biomarkers for the presymptomatic stage is important for the design of disease-modifying trials. We review the recent progress in imaging biomarkers of the presymptomatic phase of familial FTLD and discuss the imaging techniques and analysis methods, with a focus on the potential implication of these imaging techniques and their utility in specific mutation types.
Collapse
Affiliation(s)
- Qin Chen
- Department of Neurology, West China Hospital of Sichuan University, Chengdu, China.,Department of Radiology, Mayo Clinic, Rochester, MN, United States
| | - Kejal Kantarci
- Department of Radiology, Mayo Clinic, Rochester, MN, United States
| |
Collapse
|
16
|
Boeve B, Bove J, Brannelly P, Brushaber D, Coppola G, Dever R, Dheel C, Dickerson B, Dickinson S, Faber K, Fields J, Fong J, Foroud T, Forsberg L, Gavrilova R, Gearhart D, Ghoshal N, Goldman J, Graff-Radford J, Graff-Radford N, Grossman M, Haley D, Heuer H, Hsiung GYR, Huey E, Irwin D, Jones D, Jones L, Kantarci K, Karydas A, Knopman D, Kornak J, Kraft R, Kramer J, Kremers W, Kukull W, Lapid M, Lucente D, Mackenzie I, Manoochehri M, McGinnis S, Miller B, Pearlman R, Petrucelli L, Potter M, Rademakers R, Ramos EM, Rankin K, Rascovsky K, Sengdy P, Shaw L, Syrjanen J, Tatton N, Taylor J, Toga A, Trojanowski J, Weintraub S, Wong B, Wszolek Z, Boxer A, Rosen H. The longitudinal evaluation of familial frontotemporal dementia subjects protocol: Framework and methodology. Alzheimers Dement 2020; 16:22-36. [PMID: 31636026 PMCID: PMC6949411 DOI: 10.1016/j.jalz.2019.06.4947] [Citation(s) in RCA: 30] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
INTRODUCTION It is important to establish the natural history of familial frontotemporal lobar degeneration (f-FTLD) and provide clinical and biomarker data for planning these studies, particularly in the asymptomatic phase. METHODS The Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects protocol was designed to enroll and follow at least 300 subjects for more than at least three annual visits who are members of kindreds with a mutation in one of the three most common f-FTLD genes-microtubule-associated protein tau, progranulin, or chromosome 9 open reading frame 72. RESULTS We present the theoretical considerations of f-FTLD and the aims/objectives of this protocol. We also describe the design and methodology for evaluating and rating subjects, in which detailed clinical and neuropsychological assessments are performed, biofluid samples are collected, and magnetic resonance imaging scans are performed using a standard protocol. DISCUSSION These data and samples, which are available to interested investigators worldwide, will facilitate planning for upcoming disease-modifying therapeutic trials in f-FTLD.
Collapse
Affiliation(s)
| | - Jessica Bove
- University of Pennsylvania, Philadelphia, PA, USA
| | - Patrick Brannelly
- Tau Consortium, Rainwater Charitable Foundation, Fort Worth, TX, USA
| | | | | | | | | | | | - Susan Dickinson
- Association for Frontotemporal Degeneration, Radnor, PA, USA
| | - Kelley Faber
- National Cell Repository for Alzheimer's Disease and Related Dementias (NCRAD), Indiana University, Indianapolis, IN, USA
| | | | | | - Tatiana Foroud
- National Cell Repository for Alzheimer's Disease and Related Dementias (NCRAD), Indiana University, Indianapolis, IN, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | - David Irwin
- University of Pennsylvania, Philadelphia, PA, USA
| | | | | | | | | | | | | | | | | | | | - Walter Kukull
- National Alzheimer Coordinating Center (NACC), University of Washington, Seattle, WA, USA
| | | | | | - Ian Mackenzie
- University of British Columbia, Vancouver, British Columbia, Canada
| | | | | | | | | | | | - Madeline Potter
- National Cell Repository for Alzheimer's Disease and Related Dementias (NCRAD), Indiana University, Indianapolis, IN, USA
| | | | | | | | | | - Pheth Sengdy
- University of British Columbia, Vancouver, British Columbia, Canada
| | - Les Shaw
- University of Pennsylvania, Philadelphia, PA, USA
| | | | - Nadine Tatton
- Association for Frontotemporal Degeneration, Radnor, PA, USA
| | | | - Arthur Toga
- Laboratory of Neuroimaging (LONI), USC, Los Angeles, CA, USA
| | | | | | | | | | | | | |
Collapse
|
17
|
Alexander C, Pisner D, Jacova C. Predementia Brain Changes in Progranulin Mutation: A Systematic Review of Neuroimaging Evidence. Dement Geriatr Cogn Disord 2019; 47:1-18. [PMID: 30630176 DOI: 10.1159/000494968] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/06/2018] [Accepted: 10/30/2018] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND Mutations in the progranulin (GRN) gene are a major cause of familial frontotemporal dementia. They result in a loss of progranulin levels and in GRN-related brain degenerative changes that unfold over years if not decades. The aim of our review was to summarize the evidence on emerging functional and structural brain abnormalities in carriers of GRN mutations. SUMMARY We performed a systematic search for studies that used at least one modality (structural MRI, fMRI, fluorodeoxyglucose positron emission tomography, diffusion tensor imaging) to compare mutation carriers to non-carrier controls. Our search produced 13 studies published between 2008 and 2017, the majority cross-sectional, with carrier sample sizes ranging from 5 to 65. Key Messages: The aggregate findings suggest that (1) measurable brain changes are detectable in at least some mutation carriers 20-25 years prior to disease onset; (2) functional/metabolic changes progress more consistently over time than structural changes; (3) the topographic pattern is anterior to posterior, not always asymmetric, and maps onto known functional networks.
Collapse
Affiliation(s)
| | - Derek Pisner
- Department of Psychology, University of Texas, Austin, Texas, USA
| | - Claudia Jacova
- School of Graduate Psychology, Pacific University, Hillsboro, Oregon, USA,
| |
Collapse
|
18
|
Nagy D, Martens LH, Leventhal L, Chen A, Kelley C, Stoiljkovic M, Hajós M. Age-dependent emergence of neurophysiological and behavioral abnormalities in progranulin-deficient mice. ALZHEIMERS RESEARCH & THERAPY 2019; 11:88. [PMID: 31639062 PMCID: PMC6805349 DOI: 10.1186/s13195-019-0540-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/21/2019] [Accepted: 09/21/2019] [Indexed: 11/10/2022]
Abstract
Background Loss-of-function mutations in the progranulin gene cause frontotemporal dementia, a genetic, heterogeneous neurodegenerative disorder. Progranulin deficiency leads to extensive neuronal loss in the frontal and temporal lobes, altered synaptic connectivity, and behavioral alterations. Methods The chronological emergence of neurophysiological and behavioral phenotypes of Grn heterozygous and homozygous mice in the dorsomedial thalamic—medial prefrontal cortical pathway were evaluated by in vivo electrophysiology and reward-seeking/processing behavior, tested between ages 3 and 12.5 months. Results Electrophysiological recordings identified a clear age-dependent deficit in the thalamocortical circuit. Both heterozygous and homozygous mice exhibited impaired input-output relationships and paired-pulse depression, but evoked response latencies were only prolonged in heterozygotes. Furthermore, we demonstrate firstly an abnormal reward-seeking/processing behavior in the homozygous mice which correlates with previously reported neuroinflammation. Conclusion Our findings indicate that murine progranulin deficiency causes age-dependent neurophysiological and behavioral abnormalities thereby indicating their validity in modeling aspects of human frontotemporal dementia.
Collapse
Affiliation(s)
- Dávid Nagy
- Translational Neuropharmacology, Section of Comparative Medicine, Yale University School of Medicine, 310 Cedar St., New Haven, CT, 06520, USA
| | | | | | - Angela Chen
- FORUM Pharmaceuticals, Inc., Waltham, MA, 02451, USA
| | - Craig Kelley
- Translational Neuropharmacology, Section of Comparative Medicine, Yale University School of Medicine, 310 Cedar St., New Haven, CT, 06520, USA
| | - Milan Stoiljkovic
- Translational Neuropharmacology, Section of Comparative Medicine, Yale University School of Medicine, 310 Cedar St., New Haven, CT, 06520, USA
| | - Mihály Hajós
- Translational Neuropharmacology, Section of Comparative Medicine, Yale University School of Medicine, 310 Cedar St., New Haven, CT, 06520, USA.
| |
Collapse
|
19
|
Katisko K, Cajanus A, Korhonen T, Remes AM, Haapasalo A, Solje E. Prodromal and Early bvFTD: Evaluating Clinical Features and Current Biomarkers. Front Neurosci 2019; 13:658. [PMID: 31293376 PMCID: PMC6598427 DOI: 10.3389/fnins.2019.00658] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2019] [Accepted: 06/07/2019] [Indexed: 12/12/2022] Open
Abstract
Despite the current diagnostic criteria, early diagnostics of behavioral variant of frontotemporal dementia (bvFTD) has remained challenging. Patients with bvFTD often present with misleading psychiatric phenotype, and, on the other hand, impairment in memory functions have increasingly been reported. However, impaired episodic memory is currently considered as an exclusion criterion for bvFTD. Single biofluid-based or imaging biomarkers do not currently provide sufficient sensitivity or specificity for early bvFTD diagnosis at single-subject level, although studies have suggested improved accuracy with different biomarker combinations. In this mini review, we evaluate the core clinical features of early bvFTD and summarize the most potential imaging and fluid biomarkers for bvFTD diagnostics.
Collapse
Affiliation(s)
- Kasper Katisko
- Institute of Clinical Medicine - Neurology, University of Eastern Finland, Kuopio, Finland
| | - Antti Cajanus
- Institute of Clinical Medicine - Neurology, University of Eastern Finland, Kuopio, Finland
| | - Titta Korhonen
- Institute of Clinical Medicine - Neurology, University of Eastern Finland, Kuopio, Finland
| | - Anne M Remes
- Institute of Clinical Medicine - Neurology, University of Eastern Finland, Kuopio, Finland.,Neuro Center, Neurology, Kuopio University Hospital, Kuopio, Finland.,Research Unit of Clinical Neuroscience, Neurology, University of Oulu, Oulu, Finland.,Medical Research Center, Oulu University Hospital, Oulu, Finland
| | - Annakaisa Haapasalo
- A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
| | - Eino Solje
- Institute of Clinical Medicine - Neurology, University of Eastern Finland, Kuopio, Finland.,Neuro Center, Neurology, Kuopio University Hospital, Kuopio, Finland
| |
Collapse
|
20
|
Whitwell JL. FTD spectrum: Neuroimaging across the FTD spectrum. PROGRESS IN MOLECULAR BIOLOGY AND TRANSLATIONAL SCIENCE 2019; 165:187-223. [PMID: 31481163 DOI: 10.1016/bs.pmbts.2019.05.009] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Frontotemporal dementia is a complex and heterogeneous neurodegenerative disease that encompasses many clinical syndromes, pathological diseases, and genetic mutations. Neuroimaging has played a critical role in our understanding of the underlying pathophysiology of frontotemporal dementia and provided biomarkers to aid diagnosis. Early studies defined patterns of neurodegeneration and hypometabolism associated with the clinical, pathological and genetic aspects of frontotemporal dementia, with more recent studies highlighting how the breakdown of structural and functional brain networks define frontotemporal dementia. Molecular positron emission tomography ligands allowing the in vivo imaging of tau proteins have also provided important insights, although more work is needed to understand the biology of the currently available ligands.
Collapse
|
21
|
Feis RA, Bouts MJRJ, Panman JL, Jiskoot LC, Dopper EGP, Schouten TM, de Vos F, van der Grond J, van Swieten JC, Rombouts SARB. Single-subject classification of presymptomatic frontotemporal dementia mutation carriers using multimodal MRI. Neuroimage Clin 2019; 22:101718. [PMID: 30827922 PMCID: PMC6543025 DOI: 10.1016/j.nicl.2019.101718] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND Classification models based on magnetic resonance imaging (MRI) may aid early diagnosis of frontotemporal dementia (FTD) but have only been applied in established FTD cases. Detection of FTD patients in earlier disease stages, such as presymptomatic mutation carriers, may further advance early diagnosis and treatment. In this study, we aim to distinguish presymptomatic FTD mutation carriers from controls on an individual level using multimodal MRI-based classification. METHODS Anatomical MRI, diffusion tensor imaging (DTI) and resting-state functional MRI data were collected in 55 presymptomatic FTD mutation carriers (8 microtubule-associated protein Tau, 35 progranulin, and 12 chromosome 9 open reading frame 72) and 48 familial controls. We calculated grey and white matter density features from anatomical MRI scans, diffusivity features from DTI, and functional connectivity features from resting-state functional MRI. These features were applied in a recently introduced multimodal behavioural variant FTD (bvFTD) classification model, and were subsequently used to train and test unimodal and multimodal carrier-control models. Classification performance was quantified using area under the receiver operator characteristic curves (AUC). RESULTS The bvFTD model was not able to separate presymptomatic carriers from controls beyond chance level (AUC = 0.582, p = 0.078). In contrast, one unimodal and several multimodal carrier-control models performed significantly better than chance level. The unimodal model included the radial diffusivity feature and had an AUC of 0.642 (p = 0.032). The best multimodal model combined radial diffusivity and white matter density features (AUC = 0.684, p = 0.004). CONCLUSIONS FTD mutation carriers can be separated from controls with a modest AUC even before symptom-onset, using a newly created carrier-control classification model, while this was not possible using a recent bvFTD classification model. A multimodal MRI-based classification score may therefore be a useful biomarker to aid earlier FTD diagnosis. The exclusive selection of white matter features in the best performing model suggests that the earliest FTD-related pathological processes occur in white matter.
Collapse
Affiliation(s)
- Rogier A Feis
- Department of Radiology, Leiden University Medical Centre, Leiden, Netherlands; Leiden Institute for Brain and Cognition, Leiden University, Leiden, Netherlands.
| | - Mark J R J Bouts
- Department of Radiology, Leiden University Medical Centre, Leiden, Netherlands; Leiden Institute for Brain and Cognition, Leiden University, Leiden, Netherlands; Institute of Psychology, Leiden University, Leiden, Netherlands.
| | - Jessica L Panman
- Department of Radiology, Leiden University Medical Centre, Leiden, Netherlands; Department of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands.
| | - Lize C Jiskoot
- Department of Radiology, Leiden University Medical Centre, Leiden, Netherlands; Department of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands.
| | - Elise G P Dopper
- Department of Radiology, Leiden University Medical Centre, Leiden, Netherlands; Department of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands; Alzheimer Centre & Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Centre, Amsterdam, Netherlands.
| | - Tijn M Schouten
- Department of Radiology, Leiden University Medical Centre, Leiden, Netherlands; Leiden Institute for Brain and Cognition, Leiden University, Leiden, Netherlands; Institute of Psychology, Leiden University, Leiden, Netherlands.
| | - Frank de Vos
- Department of Radiology, Leiden University Medical Centre, Leiden, Netherlands; Leiden Institute for Brain and Cognition, Leiden University, Leiden, Netherlands; Institute of Psychology, Leiden University, Leiden, Netherlands.
| | | | - John C van Swieten
- Department of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands; Department of Clinical Genetics, Neuroscience Campus Amsterdam, VU University Medical Centre, Amsterdam, Netherlands.
| | - Serge A R B Rombouts
- Department of Radiology, Leiden University Medical Centre, Leiden, Netherlands; Leiden Institute for Brain and Cognition, Leiden University, Leiden, Netherlands; Institute of Psychology, Leiden University, Leiden, Netherlands.
| |
Collapse
|
22
|
Premi E, Calhoun VD, Diano M, Gazzina S, Cosseddu M, Alberici A, Archetti S, Paternicò D, Gasparotti R, van Swieten J, Galimberti D, Sanchez-Valle R, Laforce R, Moreno F, Synofzik M, Graff C, Masellis M, Tartaglia MC, Rowe J, Vandenberghe R, Finger E, Tagliavini F, de Mendonça A, Santana I, Butler C, Ducharme S, Gerhard A, Danek A, Levin J, Otto M, Frisoni G, Cappa S, Sorbi S, Padovani A, Rohrer JD, Borroni B. The inner fluctuations of the brain in presymptomatic Frontotemporal Dementia: The chronnectome fingerprint. Neuroimage 2019; 189:645-654. [PMID: 30716457 DOI: 10.1016/j.neuroimage.2019.01.080] [Citation(s) in RCA: 28] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2018] [Revised: 01/27/2019] [Accepted: 01/31/2019] [Indexed: 11/29/2022] Open
Abstract
Frontotemporal Dementia (FTD) is preceded by a long period of subtle brain changes, occurring in the absence of overt cognitive symptoms, that need to be still fully characterized. Dynamic network analysis based on resting-state magnetic resonance imaging (rs-fMRI) is a potentially powerful tool for the study of preclinical FTD. In the present study, we employed a "chronnectome" approach (recurring, time-varying patterns of connectivity) to evaluate measures of dynamic connectivity in 472 at-risk FTD subjects from the Genetic Frontotemporal dementia research Initiative (GENFI) cohort. We considered 249 subjects with FTD-related pathogenetic mutations and 223 mutation non-carriers (HC). Dynamic connectivity was evaluated using independent component analysis and sliding-time window correlation to rs-fMRI data, and meta-state measures of global brain flexibility were extracted. Results show that presymptomatic FTD exhibits diminished dynamic fluidity, visiting less meta-states, shifting less often across them, and travelling through a narrowed meta-state distance, as compared to HC. Dynamic connectivity changes characterize preclinical FTD, arguing for the desynchronization of the inner fluctuations of the brain. These changes antedate clinical symptoms, and might represent an early signature of FTD to be used as a biomarker in clinical trials.
Collapse
Affiliation(s)
- Enrico Premi
- Centre for Neurodegenerative Disorders, Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; Stroke Unit, Azienda Socio Sanitaria Territoriale Spedali Civili, Spedali Civili Hospital, Brescia, Italy
| | - Vince D Calhoun
- The Mind Research Network, Albuquerque, USA; Department of Electrical and Computer Engineering, University of New Mexico, Albuquerque, USA
| | - Matteo Diano
- Department of Psychology, University of Turin, Turin, Italy; Department of Medical and Clinical Psychology, CoRPS - Center of Research on Psychology in Somatic Diseases, Tilburg University, the Netherlands
| | - Stefano Gazzina
- Centre for Neurodegenerative Disorders, Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
| | - Maura Cosseddu
- Centre for Neurodegenerative Disorders, Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
| | - Antonella Alberici
- Centre for Neurodegenerative Disorders, Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
| | - Silvana Archetti
- Biotechnology Laboratory, Department of Diagnostic, Spedali Civili Hospital, Brescia, Italy
| | - Donata Paternicò
- Centre for Neurodegenerative Disorders, Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
| | | | - John van Swieten
- Department of Neurology, Erasmus Medical Center, Rotterdam, the Netherlands
| | - Daniela Galimberti
- Department of Pathophysiology and Transplantation, "Dino Ferrari" Center, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Milan, Italy
| | - Raquel Sanchez-Valle
- Neurology Department, Hospital Clinic, Institut d'Investigacions Biomèdiques, Barcelona, Spain
| | - Robert Laforce
- Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques, CHU de Québec, Faculté de Médecine, Université Laval, QC, Canada
| | - Fermin Moreno
- Department of Neurology, Hospital Universitario Donostia, San Sebastian, Gipuzkoa, Spain
| | - Matthis Synofzik
- Department of Cognitive Neurology, Center for Neurology, Hertie-Institute for Clinical Brain Research, Tübingen, Germany
| | - Caroline Graff
- Karolinska Institutet, Department NVS, Center for Alzheimer Research, Division of Neurogenetics, Sweden
| | - Mario Masellis
- LC Campbell Cognitive Neurology Research Unit, Sunnybrook Research Institute, Toronto, ON, Canada
| | - Maria Carmela Tartaglia
- Toronto Western Hospital, Tanz Centre for Research in Neurodegenerative Disease, Toronto, ON, Canada
| | - James Rowe
- Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
| | - Rik Vandenberghe
- Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium
| | - Elizabeth Finger
- Department of Clinical Neurological Sciences, University of Western Ontario, London, ON, Canada
| | - Fabrizio Tagliavini
- Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta, Milan, Italy
| | | | - Isabel Santana
- Neurology Department, Centro Hospitalar e Universitário de Coimbra, Portugal
| | - Chris Butler
- Department of Clinical Neurology, University of Oxford, Oxford, UK
| | - Simon Ducharme
- Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada
| | - Alex Gerhard
- Institute of Brain, Behaviour and Mental Health, The University of Manchester, Withington, Manchester, UK
| | - Adrian Danek
- Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität, Munich, German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
| | - Johannes Levin
- Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität, Munich, German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
| | - Markus Otto
- Department of Neurology, University Hospital Ulm, Ulm, Germany
| | - Giovanni Frisoni
- Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy; Memory Clinic and LANVIE-Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Geneva, Switzerland
| | - Stefano Cappa
- Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
| | - Sandro Sorbi
- Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) "Don Gnocchi", Florence, Italy
| | - Alessandro Padovani
- Centre for Neurodegenerative Disorders, Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
| | | | - Barbara Borroni
- Centre for Neurodegenerative Disorders, Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
| | | |
Collapse
|
23
|
Panman JL, Jiskoot LC, Bouts MJRJ, Meeter LHH, van der Ende EL, Poos JM, Feis RA, Kievit AJA, van Minkelen R, Dopper EGP, Rombouts SARB, van Swieten JC, Papma JM. Gray and white matter changes in presymptomatic genetic frontotemporal dementia: a longitudinal MRI study. Neurobiol Aging 2019; 76:115-124. [PMID: 30711674 DOI: 10.1016/j.neurobiolaging.2018.12.017] [Citation(s) in RCA: 55] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2018] [Revised: 12/19/2018] [Accepted: 12/27/2018] [Indexed: 10/27/2022]
Abstract
In genetic frontotemporal dementia, cross-sectional studies have identified profiles of presymptomatic neuroanatomical loss for C9orf72 repeat expansion, MAPT, and GRN mutations. In this study, we characterize longitudinal gray matter (GM) and white matter (WM) brain changes in presymptomatic frontotemporal dementia. We included healthy carriers of C9orf72 repeat expansion (n = 12), MAPT (n = 15), GRN (n = 33) mutations, and related noncarriers (n = 53), that underwent magnetic resonance imaging at baseline and 2-year follow-up. We analyzed cross-sectional baseline, follow-up, and longitudinal GM and WM changes using voxel-based morphometry and cortical thickness analysis in SPM and tract-based spatial statistics in FSL. Compared with noncarriers, C9orf72 repeat expansion carriers showed lower GM volume in the cerebellum and insula, and WM differences in the anterior thalamic radiation, at baseline and follow-up. MAPT mutation carriers showed emerging GM temporal lobe changes and longitudinal WM degeneration of the uncinate fasciculus. GRN mutation carriers did not show presymptomatic neurodegeneration. This study shows distinct presymptomatic cross-sectional and longitudinal patterns of GM and WM changes across C9orf72 repeat expansion, MAPT, and GRN mutation carriers compared with noncarriers.
Collapse
Affiliation(s)
- Jessica L Panman
- Department of Neurology, Erasmus Medical Center, Rotterdam, the Netherlands; Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands
| | - Lize C Jiskoot
- Department of Neurology, Erasmus Medical Center, Rotterdam, the Netherlands; Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands
| | - Mark J R J Bouts
- Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands; Institute of Psychology, Leiden University, Leiden, the Netherlands
| | - Lieke H H Meeter
- Department of Neurology, Erasmus Medical Center, Rotterdam, the Netherlands
| | - Emma L van der Ende
- Department of Neurology, Erasmus Medical Center, Rotterdam, the Netherlands; Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands
| | - Jackie M Poos
- Department of Neurology, Erasmus Medical Center, Rotterdam, the Netherlands; Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands
| | - Rogier A Feis
- Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands; Institute of Psychology, Leiden University, Leiden, the Netherlands; Leiden Institute for Brain and Cognition, Leiden University, Leiden, the Netherlands
| | - Anneke J A Kievit
- Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, the Netherlands
| | - Rick van Minkelen
- Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, the Netherlands
| | - Elise G P Dopper
- Department of Neurology, Erasmus Medical Center, Rotterdam, the Netherlands; Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands; Department of Neurology, VU medical Center, Amsterdam, the Netherlands
| | - Serge A R B Rombouts
- Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands; Institute of Psychology, Leiden University, Leiden, the Netherlands; Leiden Institute for Brain and Cognition, Leiden University, Leiden, the Netherlands
| | - John C van Swieten
- Department of Neurology, Erasmus Medical Center, Rotterdam, the Netherlands; Department of Clinical Genetics, VU Medical Center, Amsterdam, the Netherlands
| | - Janne M Papma
- Department of Neurology, Erasmus Medical Center, Rotterdam, the Netherlands.
| |
Collapse
|
24
|
Chan S, Bota R. Personalized TMS: role of RNA genotyping. Ment Illn 2019; 11:8-15. [PMID: 32742620 PMCID: PMC7364573 DOI: 10.1108/mij-10-2019-0004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2019] [Revised: 10/21/2019] [Accepted: 10/21/2019] [Indexed: 12/26/2022] Open
Abstract
Purpose Noninvasive brain stimulation (NIBS) such a transcranial magnetic stimulation, intermittent theta burst stimulation, transcranial direct current stimulation and electroconvulsive therapy have emerged as an efficacious and well-tolerated therapy for treatment-resistant psychiatric disorders. While novel NIBS techniques are an exciting addition to the current repertoire of neuropsychiatric therapies, their success is somewhat limited by the wide range of treatment responses seen among treated patients. Design/methodology/approach In this study, the authors will review the studies on relevant genetic polymorphisms and discuss the role of RNA genotyping in personalizing NIBS. Findings Genome studies have revealed several genetic polymorphisms that may contribute for the heterogeneity of treatment response to NIBS where the presence of certain single nucleotide polymorphisms (SNPs) are associated with responders versus nonresponders. Originality/value Historically, mental illnesses have been arguably some of the most challenging disorders to study and to treat because of the degree of biological variability across affected individuals, the role of genetic and epigenetic modifications, the diversity of clinical symptomatology and presentations and the interplay with environmental factors. In lieu of these challenges, there has been a push for personalized medicine in psychiatry that aims to optimize treatment response based on one's unique characteristics.
Collapse
Affiliation(s)
- Shawna Chan
- University of California Irvine, Irvine, California, USA
| | - Robert Bota
- University of California Irvine, Irvine, California, USA
| |
Collapse
|
25
|
Jiskoot LC, Panman JL, Meeter LH, Dopper EGP, Donker Kaat L, Franzen S, van der Ende EL, van Minkelen R, Rombouts SARB, Papma JM, van Swieten JC. Longitudinal multimodal MRI as prognostic and diagnostic biomarker in presymptomatic familial frontotemporal dementia. Brain 2019; 142:193-208. [PMID: 30508042 PMCID: PMC6308313 DOI: 10.1093/brain/awy288] [Citation(s) in RCA: 64] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2018] [Revised: 09/26/2018] [Accepted: 10/02/2018] [Indexed: 12/12/2022] Open
Abstract
Developing and validating sensitive biomarkers for the presymptomatic stage of familial frontotemporal dementia is an important step in early diagnosis and for the design of future therapeutic trials. In the longitudinal Frontotemporal Dementia Risk Cohort, presymptomatic mutation carriers and non-carriers from families with familial frontotemporal dementia due to microtubule-associated protein tau (MAPT) and progranulin (GRN) mutations underwent a clinical assessment and multimodal MRI at baseline, 2-, and 4-year follow-up. Of the cohort of 73 participants, eight mutation carriers (three GRN, five MAPT) developed clinical features of frontotemporal dementia ('converters'). Longitudinal whole-brain measures of white matter integrity (fractional anisotropy) and grey matter volume in these converters (n = 8) were compared with healthy mutation carriers ('non-converters'; n = 35) and non-carriers (n = 30) from the same families. We also assessed the prognostic performance of decline within white matter and grey matter regions of interest by means of receiver operating characteristic analyses followed by stepwise logistic regression. Longitudinal whole-brain analyses demonstrated lower fractional anisotropy values in extensive white matter regions (genu corpus callosum, forceps minor, uncinate fasciculus, and superior longitudinal fasciculus) and smaller grey matter volumes (prefrontal, temporal, cingulate, and insular cortex) over time in converters, present from 2 years before symptom onset. White matter integrity loss of the right uncinate fasciculus and genu corpus callosum provided significant classifiers between converters, non-converters, and non-carriers. Converters' within-individual disease trajectories showed a relatively gradual onset of clinical features in MAPT, whereas GRN mutations had more rapid changes around symptom onset. MAPT converters showed more decline in the uncinate fasciculus than GRN converters, and more decline in the genu corpus callosum in GRN than MAPT converters. Our study confirms the presence of spreading predominant frontotemporal pathology towards symptom onset and highlights the value of multimodal MRI as a prognostic biomarker in familial frontotemporal dementia.
Collapse
Affiliation(s)
- Lize C Jiskoot
- Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
- Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands
| | - Jessica L Panman
- Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
- Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands
| | - Lieke H Meeter
- Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Elise G P Dopper
- Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
- Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands
- Department of Neurology, VU Medical Center, Amsterdam, The Netherlands
| | - Laura Donker Kaat
- Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
- Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands
| | - Sanne Franzen
- Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
| | | | - Rick van Minkelen
- Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Serge A R B Rombouts
- Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands
- Institute of Psychology, Leiden University, Leiden, The Netherlands
- Leiden Institute for Brain and Cognition, Leiden University, Leiden, The Netherlands
| | - Janne M Papma
- Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
| | - John C van Swieten
- Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
| |
Collapse
|
26
|
Jiskoot LC, Bocchetta M, Nicholas JM, Cash DM, Thomas D, Modat M, Ourselin S, Rombouts SA, Dopper EG, Meeter LH, Panman JL, van Minkelen R, van der Ende EL, Donker Kaat L, Pijnenburg YA, Borroni B, Galimberti D, Masellis M, Tartaglia MC, Rowe J, Graff C, Tagliavini F, Frisoni GB, Laforce R, Finger E, de Mendonça A, Sorbi S, Papma JM, van Swieten JC, Rohrer JD. Presymptomatic white matter integrity loss in familial frontotemporal dementia in the GENFI cohort: A cross-sectional diffusion tensor imaging study. Ann Clin Transl Neurol 2018; 5:1025-1036. [PMID: 30250860 PMCID: PMC6144447 DOI: 10.1002/acn3.601] [Citation(s) in RCA: 36] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2018] [Accepted: 06/08/2018] [Indexed: 12/12/2022] Open
Abstract
Objective We aimed to investigate mutation-specific white matter (WM) integrity changes in presymptomatic and symptomatic mutation carriers of the C9orf72,MAPT, and GRN mutations by use of diffusion-weighted imaging within the Genetic Frontotemporal dementia Initiative (GENFI) study. Methods One hundred and forty mutation carriers (54 C9orf72, 30 MAPT, 56 GRN), 104 presymptomatic and 36 symptomatic, and 115 noncarriers underwent 3T diffusion tensor imaging. Linear mixed effects models were used to examine the association between diffusion parameters and years from estimated symptom onset in C9orf72,MAPT, and GRN mutation carriers versus noncarriers. Post hoc analyses were performed on presymptomatic mutation carriers only, as well as left-right asymmetry analyses on GRN mutation carriers versus noncarriers. Results Diffusion changes in C9orf72 mutation carriers are present significantly earlier than both MAPT and GRN mutation carriers - characteristically in the posterior thalamic radiation and more posteriorly located tracts (e.g., splenium of the corpus callosum, posterior corona radiata), as early as 30 years before estimated symptom onset. MAPT mutation carriers showed early involvement of the uncinate fasciculus and cingulum, sparing the internal capsule, whereas involvement of the anterior and posterior internal capsule was found in GRN. Restricting analyses to presymptomatic mutation carriers only, similar - albeit less extensive - patterns were found: posteriorly located WM tracts (e.g., posterior thalamic radiation, splenium of the corpus callosum, posterior corona radiata) in presymptomatic C9orf72, the uncinate fasciculus in presymptomatic MAPT, and the internal capsule (anterior and posterior limbs) in presymptomatic GRN mutation carriers. In GRN, most tracts showed significant left-right differences in one or more diffusion parameter, with the most consistent results being found in the UF, EC, RPIC, and ALIC. Interpretation This study demonstrates the presence of early and widespread WM integrity loss in presymptomatic FTD, and suggests a clear genotypic "fingerprint." Our findings corroborate the notion of FTD as a network-based disease, where changes in connectivity are some of the earliest detectable features, and identify diffusion tensor imaging as a potential neuroimaging biomarker for disease-tracking and -staging in presymptomatic to early-stage familial FTD.
Collapse
|
27
|
|
28
|
Feis RA, Bouts MJRJ, Panman JL, Jiskoot LC, Dopper EGP, Schouten TM, de Vos F, van der Grond J, van Swieten JC, Rombouts SARB. Single-subject classification of presymptomatic frontotemporal dementia mutation carriers using multimodal MRI. Neuroimage Clin 2018; 20:188-196. [PMID: 30094168 PMCID: PMC6072645 DOI: 10.1016/j.nicl.2018.07.014] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2018] [Revised: 06/29/2018] [Accepted: 07/15/2018] [Indexed: 11/30/2022]
Abstract
Background Classification models based on magnetic resonance imaging (MRI) may aid early diagnosis of frontotemporal dementia (FTD) but have only been applied in established FTD cases. Detection of FTD patients in earlier disease stages, such as presymptomatic mutation carriers, may further advance early diagnosis and treatment. In this study, we aim to distinguish presymptomatic FTD mutation carriers from controls on an individual level using multimodal MRI-based classification. Methods Anatomical MRI, diffusion tensor imaging (DTI) and resting-state functional MRI data were collected in 55 presymptomatic FTD mutation carriers (8 microtubule-associated protein Tau, 35 progranulin, and 12 chromosome 9 open reading frame 72) and 48 familial controls. We calculated grey and white matter density features from anatomical MRI scans, diffusivity features from DTI, and functional connectivity features from resting-state functional MRI. These features were applied in a recently introduced multimodal behavioural variant FTD (bvFTD) classification model, and were subsequently used to train and test unimodal and multimodal carrier-control models. Classification performance was quantified using area under the receiver operator characteristic curves (AUC). Results The bvFTD model was not able to separate presymptomatic carriers from controls beyond chance level (AUC = 0.570, p = 0.11). In contrast, one unimodal and several multimodal carrier-control models performed significantly better than chance level. The unimodal model included the radial diffusivity feature and had an AUC of 0.646 (p = 0.021). The best multimodal model combined radial diffusivity and white matter density features (AUC = 0.680, p = 0.005). Conclusions FTD mutation carriers can be separated from controls with a modest AUC even before symptom-onset, using a newly created carrier-control classification model, while this was not possible using a recent bvFTD classification model. A multimodal MRI-based classification score may therefore be a useful biomarker to aid earlier FTD diagnosis. The exclusive selection of white matter features in the best performing model suggests that the earliest FTD-related pathological processes occur in white matter.
Collapse
Key Words
- (bv)FTD, (behavioural variant) Frontotemporal dementia
- (rs-f)MRI, (resting-state functional) Magnetic resonance imaging
- 3DT1w, 3-dimensional T1-weighted
- AUC, Area under the receiver operating characteristics curve
- AxD, Axial diffusivity
- C9orf72, Chromosome 9 open reading frame 72
- C9orf72, human
- DTI, Diffusion tensor imaging
- DWI, Diffusion-weighted imaging
- Diffusion Tensor Imaging
- FA, Fractional anisotropy
- FCor, Full correlations
- Frontotemporal dementia
- GM, Grey matter
- GMD, Grey matter density
- GRN protein, human
- GRN, Progranulin
- ICA, Independent component analysis
- MAPT protein, human
- MAPT, Microtubule-associated protein Tau
- MD, Mean diffusivity
- MMSE, Mini-mental state examination
- Multimodal MRI
- Pcor, Sparse L1-regularised partial correlations
- RD, Radial diffusivity
- ROC, Receiver operating characteristics
- Resting-state functional MRI
- TBSS, Tract-based spatial statistics
- WM, White matter
- WMD, White matter density
- classification
- machine learning
Collapse
Affiliation(s)
- Rogier A Feis
- Department of Radiology, Leiden University Medical Centre, Leiden, the Netherlands; Leiden Institute for Brain and Cognition, Leiden University, Leiden, the Netherlands.
| | - Mark J R J Bouts
- Department of Radiology, Leiden University Medical Centre, Leiden, the Netherlands; Leiden Institute for Brain and Cognition, Leiden University, Leiden, the Netherlands; Institute of Psychology, Leiden University, Leiden, the Netherlands.
| | - Jessica L Panman
- Department of Radiology, Leiden University Medical Centre, Leiden, the Netherlands; Department of Neurology, Erasmus Medical Centre, Rotterdam, the Netherlands.
| | - Lize C Jiskoot
- Department of Radiology, Leiden University Medical Centre, Leiden, the Netherlands; Department of Neurology, Erasmus Medical Centre, Rotterdam, the Netherlands.
| | - Elise G P Dopper
- Department of Radiology, Leiden University Medical Centre, Leiden, the Netherlands; Department of Neurology, Erasmus Medical Centre, Rotterdam, the Netherlands; Alzheimer Centre & Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Centre, Amsterdam, the Netherlands.
| | - Tijn M Schouten
- Department of Radiology, Leiden University Medical Centre, Leiden, the Netherlands; Leiden Institute for Brain and Cognition, Leiden University, Leiden, the Netherlands; Institute of Psychology, Leiden University, Leiden, the Netherlands.
| | - Frank de Vos
- Department of Radiology, Leiden University Medical Centre, Leiden, the Netherlands; Leiden Institute for Brain and Cognition, Leiden University, Leiden, the Netherlands; Institute of Psychology, Leiden University, Leiden, the Netherlands.
| | - Jeroen van der Grond
- Department of Radiology, Leiden University Medical Centre, Leiden, the Netherlands.
| | - John C van Swieten
- Department of Neurology, Erasmus Medical Centre, Rotterdam, the Netherlands; Department of Clinical Genetics, Neuroscience Campus Amsterdam, VU University Medical Centre, Amsterdam, the Netherlands.
| | - Serge A R B Rombouts
- Department of Radiology, Leiden University Medical Centre, Leiden, the Netherlands; Leiden Institute for Brain and Cognition, Leiden University, Leiden, the Netherlands; Institute of Psychology, Leiden University, Leiden, the Netherlands.
| |
Collapse
|
29
|
Olm CA, McMillan CT, Irwin DJ, Van Deerlin VM, Cook PA, Gee JC, Grossman M. Longitudinal structural gray matter and white matter MRI changes in presymptomatic progranulin mutation carriers. Neuroimage Clin 2018; 19:497-506. [PMID: 29984158 PMCID: PMC6029561 DOI: 10.1016/j.nicl.2018.05.017] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2017] [Revised: 03/29/2018] [Accepted: 05/13/2018] [Indexed: 11/21/2022]
Abstract
Introduction Mutations in the progranulin (GRN) gene are a major source of inherited frontotemporal degeneration (FTD) spectrum disorders associated with TDP-43 proteinopathy. We use structural MRI to identify regions of baseline differences and longitudinal changes in gray matter (GM) and white matter (WM) in presymptomatic GRN mutation carriers (pGRN+) compared to young controls (yCTL). Methods Cognitively intact first-degree relatives of symptomatic GRN+ FTD patients with identified GRN mutations (pGRN+; N = 11, mean age = 41.4) and matched yCTL (N = 11, mean age = 53.6) were identified. They completed a MRI session with T1-weighted imaging to assess GM density (GMD) and diffusion-weighted imaging (DWI) to assess fractional anisotropy (FA). Participants completed a follow-up session with T1 and DWI imaging (pGRN+ mean interval 2.20 years; yCTL mean interval 3.27 years). Annualized changes of GMD and FA were also compared. Results Relative to yCTL, pGRN+ individuals displayed reduced GMD at baseline in bilateral orbitofrontal, insular, and anterior temporal cortices. pGRN+ also showed greater annualized GMD changes than yCTL at follow-up in right orbitofrontal and left occipital cortices. We also observed reduced FA at baseline in bilateral superior longitudinal fasciculus, left corticospinal tract, and frontal corpus callosum in pGRN+ relative to yCTL, and pGRN+ displayed greater annualized longitudinal FA change in right superior longitudinal fasciculus and frontal corpus callosum. Conclusions Longitudinal MRI provides evidence of progressive GM and WM changes in pGRN+ participants relative to yCTL. Structural MRI illustrates the natural history of presymptomatic GRN carriers, and may provide an endpoint during disease-modifying treatment trials for pGRN+ individuals at risk for FTD.
Collapse
Key Words
- AD, axial diffusivity
- BA, Brodmann area
- CST, corticospinal tract
- DWI, diffusion-weighted imaging
- FA, fractional anisotropy
- FTD, frontotemporal degeneration
- Frontotemporal lobar degeneration
- GM, gray matter
- GMD, gray matter density
- GRN+, symptomatic progranulin mutation carriers
- GRN, progranulin
- IFO, inferior fronto-occipital fasciculus
- ILF, inferior longitudinal fasciculus
- Longitudinal
- MD, mean diffusivity
- Magnetic resonance imaging
- Neuroimaging
- Presymptomatic
- Progranulin
- RD, radial diffusivity
- ROI, region of interest
- SLF, superior longitudinal fasciculus
- WM, white matter
- eCTL, elderly healthy controls
- pGRN+, presymptomatic progranulin mutation carriers
- yCTL, young healthy controls
Collapse
Affiliation(s)
- Christopher A Olm
- Penn Frontotemporal Degeneration Center, Department of Neurology, University of Pennsylvania, Philadelphia, PA, United States; Penn Image Computing and Science Laboratory, Department of Radiology, University of Pennsylvania, Philadelphia, PA, United States
| | - Corey T McMillan
- Penn Frontotemporal Degeneration Center, Department of Neurology, University of Pennsylvania, Philadelphia, PA, United States
| | - David J Irwin
- Penn Frontotemporal Degeneration Center, Department of Neurology, University of Pennsylvania, Philadelphia, PA, United States; Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, United States
| | - Vivianna M Van Deerlin
- Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, United States
| | - Philip A Cook
- Penn Image Computing and Science Laboratory, Department of Radiology, University of Pennsylvania, Philadelphia, PA, United States
| | - James C Gee
- Penn Image Computing and Science Laboratory, Department of Radiology, University of Pennsylvania, Philadelphia, PA, United States
| | - Murray Grossman
- Penn Frontotemporal Degeneration Center, Department of Neurology, University of Pennsylvania, Philadelphia, PA, United States.
| |
Collapse
|
30
|
Alexander C, Zeithamova D, Hsiung GYR, Mackenzie IR, Jacova C. Decreased Prefrontal Activation during Matrix Reasoning in Predementia Progranulin Mutation Carriers. J Alzheimers Dis 2018; 62:583-589. [DOI: 10.3233/jad-170716] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
| | | | - Ging-Yuek R. Hsiung
- Division of Neurology, University of British Columbia, Vancouver, BC, Canada
| | - Ian R. Mackenzie
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada
| | - Claudia Jacova
- School of Graduate Psychology, Pacific University, Hillsboro, OR, USA
- Division of Neurology, University of British Columbia, Vancouver, BC, Canada
| |
Collapse
|
31
|
Popuri K, Dowds E, Beg MF, Balachandar R, Bhalla M, Jacova C, Buller A, Slack P, Sengdy P, Rademakers R, Wittenberg D, Feldman HH, Mackenzie IR, Hsiung GYR. Gray matter changes in asymptomatic C9orf72 and GRN mutation carriers. Neuroimage Clin 2018; 18:591-598. [PMID: 29845007 PMCID: PMC5964622 DOI: 10.1016/j.nicl.2018.02.017] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2017] [Revised: 01/25/2018] [Accepted: 02/16/2018] [Indexed: 01/10/2023]
Abstract
Frontotemporal dementia (FTD) is a neurodegenerative disease with a strong genetic basis. Understanding the structural brain changes during pre-symptomatic stages may allow for earlier diagnosis of patients suffering from FTD; therefore, we investigated asymptomatic members of FTD families with mutations in C9orf72 and granulin (GRN) genes. Clinically asymptomatic subjects from families with C9orf72 mutation (15 mutation carriers, C9orf72+; and 23 non-carriers, C9orf72-) and GRN mutations (9 mutation carriers, GRN+; and 15 non-carriers, GRN-) underwent structural neuroimaging (MRI). Cortical thickness and subcortical gray matter volumes were calculated using FreeSurfer. Group differences were evaluated, correcting for age, sex and years to mean age of disease onset within the subject's family. Mean age of C9orf72+ and C9orf72- were 42.6 ± 11.3 and 49.7 ± 15.5 years, respectively; while GRN+ and GRN- groups were 50.1 ± 8.7 and 53.2 ± 11.2 years respectively. The C9orf72+ group exhibited cortical thinning in the temporal, parietal and frontal regions, as well as reduced volumes of bilateral thalamus and left caudate compared to the entire group of mutation non-carriers (NC: C9orf72- and GRN- combined). In contrast, the GRN+ group did not show any significant differences compared to NC. C9orf72 mutation carriers demonstrate a pattern of reduced gray matter on MRI prior to symptom onset compared to GRN mutation carriers. These findings suggest that the preclinical course of FTD differs depending on the genetic basis and that the choice of neuroimaging biomarkers for FTD may need to take into account the specific genes involved in causing the disease.
Collapse
Affiliation(s)
- Karteek Popuri
- School of Engineering Science, Simon Fraser University, Canada
| | - Emma Dowds
- Division of Neurology, Department of Medicine, University of British Columbia, Canada
| | | | | | - Mahadev Bhalla
- School of Engineering Science, Simon Fraser University, Canada
| | - Claudia Jacova
- School of Professional Psychology, Pacific University, Hillsboro, OR, USA
| | - Adrienne Buller
- School of Engineering Science, Simon Fraser University, Canada
| | - Penny Slack
- Division of Neurology, Department of Medicine, University of British Columbia, Canada
| | - Pheth Sengdy
- Division of Neurology, Department of Medicine, University of British Columbia, Canada
| | - Rosa Rademakers
- Department of Neuroscience, Mayo Clinic Jacksonville, FL, USA
| | - Dana Wittenberg
- Division of Neurology, Department of Medicine, University of British Columbia, Canada
| | - Howard H Feldman
- Department of Neurosciences, University of California San Diego, CA, USA
| | - Ian R Mackenzie
- Department of Pathology and Laboratory Medicine, University of British Columbia, Canada
| | - Ging-Yuek R Hsiung
- Division of Neurology, Department of Medicine, University of British Columbia, Canada.
| |
Collapse
|
32
|
Borroni B, Benussi A, Premi E, Alberici A, Marcello E, Gardoni F, Di Luca M, Padovani A. Biological, Neuroimaging, and Neurophysiological Markers in Frontotemporal Dementia: Three Faces of the Same Coin. J Alzheimers Dis 2018; 62:1113-1123. [PMID: 29171998 PMCID: PMC5870000 DOI: 10.3233/jad-170584] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/06/2017] [Indexed: 12/12/2022]
Abstract
Frontotemporal dementia (FTD) is a heterogeneous clinical, genetic, and neuropathological disorder. Clinical diagnosis and prediction of neuropathological substrates are hampered by heterogeneous pictures. Diagnostic markers are key in clinical trials to differentiate FTD from other neurodegenerative dementias. In the same view, identifying the neuropathological hallmarks of the disease is key in light of future disease-modifying treatments. The aim of the present review is to unravel the progress in biomarker discovery, discussing the potential applications of available biological, imaging, and neurophysiological markers.
Collapse
Affiliation(s)
- Barbara Borroni
- Department of Clinical and Experimental Sciences, Neurology Unit, University of Brescia, Brescia, Italy
| | - Alberto Benussi
- Department of Clinical and Experimental Sciences, Neurology Unit, University of Brescia, Brescia, Italy
| | - Enrico Premi
- Department of Clinical and Experimental Sciences, Neurology Unit, University of Brescia, Brescia, Italy
| | - Antonella Alberici
- Department of Clinical and Experimental Sciences, Neurology Unit, University of Brescia, Brescia, Italy
| | - Elena Marcello
- Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy
| | - Fabrizio Gardoni
- Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy
| | - Monica Di Luca
- Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy
| | - Alessandro Padovani
- Department of Clinical and Experimental Sciences, Neurology Unit, University of Brescia, Brescia, Italy
| |
Collapse
|
33
|
Gazzina S, Benussi A, Premi E, Paternicò D, Cristillo V, Dell’Era V, Cosseddu M, Archetti S, Alberici A, Gasparotti R, Padovani A, Borroni B. Neuroanatomical Correlates of Transcranial Magnetic Stimulation in Presymptomatic Granulin Mutation Carriers. Brain Topogr 2017; 31:488-497. [DOI: 10.1007/s10548-017-0612-9] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2017] [Accepted: 12/09/2017] [Indexed: 12/13/2022]
|
34
|
Chitramuthu BP, Bennett HPJ, Bateman A. Progranulin: a new avenue towards the understanding and treatment of neurodegenerative disease. Brain 2017; 140:3081-3104. [PMID: 29053785 DOI: 10.1093/brain/awx198] [Citation(s) in RCA: 92] [Impact Index Per Article: 13.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2016] [Accepted: 06/26/2017] [Indexed: 12/14/2022] Open
Abstract
Progranulin, a secreted glycoprotein, is encoded in humans by the single GRN gene. Progranulin consists of seven and a half, tandemly repeated, non-identical copies of the 12 cysteine granulin motif. Many cellular processes and diseases are associated with this unique pleiotropic factor that include, but are not limited to, embryogenesis, tumorigenesis, inflammation, wound repair, neurodegeneration and lysosome function. Haploinsufficiency caused by autosomal dominant mutations within the GRN gene leads to frontotemporal lobar degeneration, a progressive neuronal atrophy that presents in patients as frontotemporal dementia. Frontotemporal dementia is an early onset form of dementia, distinct from Alzheimer's disease. The GRN-related form of frontotemporal lobar dementia is a proteinopathy characterized by the appearance of neuronal inclusions containing ubiquitinated and fragmented TDP-43 (encoded by TARDBP). The neurotrophic and neuro-immunomodulatory properties of progranulin have recently been reported but are still not well understood. Gene delivery of GRN in experimental models of Alzheimer's- and Parkinson's-like diseases inhibits phenotype progression. Here we review what is currently known concerning the molecular function and mechanism of action of progranulin in normal physiological and pathophysiological conditions in both in vitro and in vivo models. The potential therapeutic applications of progranulin in treating neurodegenerative diseases are highlighted.
Collapse
Affiliation(s)
- Babykumari P Chitramuthu
- Endocrine Research Laboratory, Royal Victoria Hospital, and McGill University Health Centre Research Institute, Centre for Translational Biology, Platform in Metabolic Disorders and Complications, 1001 Decarie Boulevard, QC, Canada, H4A 3J1
| | - Hugh P J Bennett
- Endocrine Research Laboratory, Royal Victoria Hospital, and McGill University Health Centre Research Institute, Centre for Translational Biology, Platform in Metabolic Disorders and Complications, 1001 Decarie Boulevard, QC, Canada, H4A 3J1
| | - Andrew Bateman
- Endocrine Research Laboratory, Royal Victoria Hospital, and McGill University Health Centre Research Institute, Centre for Translational Biology, Platform in Metabolic Disorders and Complications, 1001 Decarie Boulevard, QC, Canada, H4A 3J1
| |
Collapse
|
35
|
Papma JM, Jiskoot LC, Panman JL, Dopper EG, den Heijer T, Donker Kaat L, Pijnenburg YA, Meeter LH, van Minkelen R, Rombouts SA, van Swieten JC. Cognition and gray and white matter characteristics of presymptomatic C9orf72 repeat expansion. Neurology 2017; 89:1256-1264. [DOI: 10.1212/wnl.0000000000004393] [Citation(s) in RCA: 68] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2017] [Accepted: 06/29/2017] [Indexed: 11/15/2022] Open
Abstract
Objective:To investigate cognitive function, gray matter volume, and white matter integrity in the presymptomatic stage of chromosome 9 open reading frame 72 repeat expansion (C9orf72RE).Methods:Presymptomatic C9orf72RE carriers (n = 18) and first-degree family members without a pathogenic expansion (healthy controls [HC], n = 15) underwent a standardized protocol of neuropsychological tests, T1-weighted MRI, and diffusion tensor imaging within our cohort study of autosomal dominant frontotemporal dementia (FTD). We investigated group differences in cognitive function, gray matter volume through voxel-based morphometry, and white matter integrity by means of tract-based spatial statistics. We correlated cognitive change with underlying gray or white matter.Results:Our data demonstrate lower scores on letter fluency, Stroop card I, and Stroop card III, accompanied by white matter integrity loss in tracts connecting the frontal lobe, the thalamic radiation, and tracts associated with motor functioning in presymptomatic C9orf72RE compared with HC. In a subgroup of C9orf72RE carriers above 40 years of age, we found gray matter volume loss in the thalamus, cerebellum, and parietal and temporal cortex. We found no significant relationship between subtle cognitive decline and underlying gray or white matter.Conclusions:This study demonstrates that a decline in cognitive functioning, white matter integrity, and gray matter volumes are present in presymptomatic C9orf72RE carriers. These findings suggest that neuropsychological assessment, T1-weighted MRI, and diffusion tensor imaging might be useful to identify early biomarkers in the presymptomatic stage of FTD or amyotrophic lateral sclerosis.
Collapse
|
36
|
Meeter LH, Kaat LD, Rohrer JD, van Swieten JC. Imaging and fluid biomarkers in frontotemporal dementia. Nat Rev Neurol 2017. [PMID: 28621768 DOI: 10.1038/nrneurol.2017.75] [Citation(s) in RCA: 133] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Frontotemporal dementia (FTD), the second most common type of presenile dementia, is a heterogeneous neurodegenerative disease characterized by progressive behavioural and/or language problems, and includes a range of clinical, genetic and pathological subtypes. The diagnostic process is hampered by this heterogeneity, and correct diagnosis is becoming increasingly important to enable future clinical trials of disease-modifying treatments. Reliable biomarkers will enable us to better discriminate between FTD and other forms of dementia and to predict disease progression in the clinical setting. Given that different underlying pathologies probably require specific pharmacological interventions, robust biomarkers are essential for the selection of patients with specific FTD subtypes. This Review emphasizes the increasing availability and potential applications of structural and functional imaging biomarkers, and cerebrospinal fluid and blood fluid biomarkers in sporadic and genetic FTD. The relevance of new MRI modalities - such as voxel-based morphometry, diffusion tensor imaging and arterial spin labelling - in the early stages of FTD is discussed, together with the ability of these modalities to classify FTD subtypes. We highlight promising new fluid biomarkers for staging and monitoring of FTD, and underline the importance of large, multicentre studies of individuals with presymptomatic FTD. Harmonization in the collection and analysis of data across different centres is crucial for the implementation of new biomarkers in clinical practice, and will become a great challenge in the next few years.
Collapse
Affiliation(s)
- Lieke H Meeter
- Department of Neurology, Erasmus Medical Center, 's Gravendijkwal 230, 3015 CE Rotterdam, Netherlands
| | - Laura Donker Kaat
- Department of Neurology, Erasmus Medical Center, 's Gravendijkwal 230, 3015 CE Rotterdam, Netherlands.,Department of Clinical Genetics, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, Netherlands
| | - Jonathan D Rohrer
- Dementia Research Centre, Department of Neurodegenerative diseases, Institute of Neurology, Queen Square, University College London, London WC1N 3BG, UK
| | - John C van Swieten
- Department of Neurology, Erasmus Medical Center, 's Gravendijkwal 230, 3015 CE Rotterdam, Netherlands.,Department of Clinical Genetics, VU University Medical Center, De Boelelaan 1118, 1081 HZ Amsterdam, Netherlands
| |
Collapse
|
37
|
Gordon E, Rohrer JD, Fox NC. Advances in neuroimaging in frontotemporal dementia. J Neurochem 2017; 138 Suppl 1:193-210. [PMID: 27502125 DOI: 10.1111/jnc.13656] [Citation(s) in RCA: 61] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2016] [Revised: 05/02/2016] [Accepted: 05/03/2016] [Indexed: 12/12/2022]
Abstract
Frontotemporal dementia (FTD) is a clinically and neuroanatomically heterogeneous neurodegenerative disorder with multiple underlying genetic and pathological causes. Whilst initial neuroimaging studies highlighted the presence of frontal and temporal lobe atrophy or hypometabolism as the unifying feature in patients with FTD, more detailed studies have revealed diverse patterns across individuals, with variable frontal or temporal predominance, differing degrees of asymmetry, and the involvement of other cortical areas including the insula and cingulate, as well as subcortical structures such as the basal ganglia and thalamus. Recent advances in novel imaging modalities including diffusion tensor imaging, resting-state functional magnetic resonance imaging and molecular positron emission tomography imaging allow the possibility of investigating alterations in structural and functional connectivity and the visualisation of pathological protein deposition. This review will cover the major imaging modalities currently used in research and clinical practice, focusing on the key insights they have provided into FTD, including the onset and evolution of pathological changes and also importantly their utility as biomarkers for disease detection and staging, differential diagnosis and measurement of disease progression. Validating neuroimaging biomarkers that are able to accomplish these tasks will be crucial for the ultimate goal of powering upcoming clinical trials by correctly stratifying patient enrolment and providing sensitive markers for evaluating the effects and efficacy of disease-modifying therapies. This review describes the key insights provided by research into the major neuroimaging modalities currently used in research and clinical practice, including what they tell us about the onset and evolution of FTD and how they may be used as biomarkers for disease detection and staging, differential diagnosis and measurement of disease progression. This article is part of the Frontotemporal Dementia special issue.
Collapse
Affiliation(s)
- Elizabeth Gordon
- Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK
| | - Jonathan D Rohrer
- Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK
| | - Nick C Fox
- Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK
| |
Collapse
|
38
|
Premi E, Cauda F, Costa T, Diano M, Gazzina S, Gualeni V, Alberici A, Archetti S, Magoni M, Gasparotti R, Padovani A, Borroni B. Looking for Neuroimaging Markers in Frontotemporal Lobar Degeneration Clinical Trials: A Multi-Voxel Pattern Analysis Study in Granulin Disease. J Alzheimers Dis 2016; 51:249-62. [DOI: 10.3233/jad-150340] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Affiliation(s)
- Enrico Premi
- Centre for Ageing Brain and Neurodegenerative Disorders, Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
- Stroke Unit, Azienda Ospedaliera “Spedali Civili”, “Spedali Civili” Hospital, Brescia, Italy
| | - Franco Cauda
- GCS fMRI Koelliker Hospital, Turin, Italy
- Department of Psychology, University of Turin, Turin, Italy
| | - Tommaso Costa
- GCS fMRI Koelliker Hospital, Turin, Italy
- Department of Psychology, University of Turin, Turin, Italy
| | - Matteo Diano
- GCS fMRI Koelliker Hospital, Turin, Italy
- Department of Psychology, University of Turin, Turin, Italy
| | - Stefano Gazzina
- Centre for Ageing Brain and Neurodegenerative Disorders, Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
| | - Vera Gualeni
- Centre for Ageing Brain and Neurodegenerative Disorders, Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
| | - Antonella Alberici
- Centre for Ageing Brain and Neurodegenerative Disorders, Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
| | - Silvana Archetti
- III Laboratory of Analyses, Azienda Ospedaliera “Spedali Civili”, “Spedali Civili” Hospital, Brescia, Italy
| | - Mauro Magoni
- Stroke Unit, Azienda Ospedaliera “Spedali Civili”, “Spedali Civili” Hospital, Brescia, Italy
| | - Roberto Gasparotti
- Neuroradiology Unit, Department of Surgery, Radiology and Public Health, University of Brescia, Brescia, Italy
| | - Alessandro Padovani
- Centre for Ageing Brain and Neurodegenerative Disorders, Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
| | - Barbara Borroni
- Centre for Ageing Brain and Neurodegenerative Disorders, Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
| |
Collapse
|
39
|
Abstract
The advances in diffusion-weighted imaging (DWI), diffusion tensor imaging (DTI), and functional magnetic resonance imaging (fMRI) over the last 20 years have vastly contributed to improving the understanding of the brain structure and function in patients with many diseases of the central nervous system (CNS). DWI is commonly used, for instance, in the diagnostic workup of stroke, CNS neoplasia, and rapidly progressive dementia cases. The new DTI methods provide more specific information about the most destructive aspects of tumors, neurodegenerative dementia, and multiple sclerosis pathology and give a more complete picture of the complex pathologic mechanisms of these conditions. More recently, fMRI has provided insight to the mechanisms of brain adaptation and plasticity to damage related to many neurologic conditions and has further extended our ability to understand the functional significance of pathologic changes in these diseases. Although at present fMRI does not have a role in the diagnosis, routine assessment, and monitoring of neurologic diseases, significant efforts are under way in order to achieve harmonization of both acquisition and postprocessing procedures, which are likely to contribute to a significant change of the clinical scenario.
Collapse
Affiliation(s)
- Massimo Filippi
- Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
| | - Federica Agosta
- Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy
| |
Collapse
|
40
|
Filippi M, Agosta F, Ferraro PM. Charting Frontotemporal Dementia: From Genes to Networks. J Neuroimaging 2015; 26:16-27. [PMID: 26617288 DOI: 10.1111/jon.12316] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2015] [Revised: 10/19/2015] [Accepted: 10/20/2015] [Indexed: 12/11/2022] Open
Abstract
Frontotemporal dementia (FTD) is a genetically and clinically heterogeneous syndrome that is characterized by overlapping clinical symptoms involving behavior, personality, language and/or motor functions and degeneration of the frontal and temporal lobes. The term frontotemporal lobar degeneration (FTLD) is used to describe the proteinopathies associated with clinical FTD. Emerging evidence from network-based neuroimaging studies, such as resting state functional MRI and diffusion tensor MRI studies, have implicated specific large-scale brain networks in the pathogenesis of FTD syndromes, suggesting a new paradigm for explaining the distributed and heterogeneous spreading patterns of pathological proteins in FTLD. In this review, we overview recent research on the study of FTD syndromes as connectivity disorders in symptomatic patients as well as genotype-specific changes in asymptomatic FTD-related gene mutation carriers. Characterizing brain network breakdown in these subjects using neuroimaging may help anticipate the diagnosis and perhaps prevent the devastating impact of FTD.
Collapse
Affiliation(s)
- Massimo Filippi
- Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.,Department of Neurology, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy
| | - Federica Agosta
- Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy
| | - Pilar M Ferraro
- Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy
| |
Collapse
|
41
|
Hopkins SAA, Chan D. Key emerging issues in frontotemporal dementia. J Neurol 2015; 263:407-413. [PMID: 26338811 DOI: 10.1007/s00415-015-7880-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2015] [Accepted: 08/11/2015] [Indexed: 12/12/2022]
Abstract
Frontotemporal dementia (FTD) encompasses the syndromes of behavioural variant FTD (bvFTD) and primary progressive aphasia (PPA) and refers to those neurodegenerative diseases characterised by predominant pathological involvement of the frontal and temporal lobes. Recent years have witnessed major advances in the clinical characterisation of FTD, reflected in the publication of updated diagnostic criteria for bvFTD and PPA, and the discovery of new pathogenic mutations has added to the understanding of genotype-phenotype interactions and of disease mechanisms. Emerging results from longitudinal studies of familial FTD show that imaging and cognitive changes occur years before symptom onset and such studies may yield biomarkers of early disease that in turn will facilitate earlier diagnosis. The hope and (guarded) expectation is that these advances may together herald the beginning of the end of the chapter in which FTD is considered an inexorably progressive and untreatable condition.
Collapse
Affiliation(s)
- Sarah A A Hopkins
- Department of Medicine for the Elderly, Addenbrooke's Hospital, Hills Road, Cambridge, CB2 0QQ, UK
| | - Dennis Chan
- Department of Clinical Neurosciences, Herchel Smith Building for Brain and Mind Sciences, University of Cambridge, Forvie Site, Robinson Way, Cambridge, CB2 0SZ, UK.
| |
Collapse
|
42
|
Benussi A, Padovani A, Borroni B. Phenotypic Heterogeneity of Monogenic Frontotemporal Dementia. Front Aging Neurosci 2015; 7:171. [PMID: 26388768 PMCID: PMC4555036 DOI: 10.3389/fnagi.2015.00171] [Citation(s) in RCA: 80] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2015] [Accepted: 08/19/2015] [Indexed: 12/12/2022] Open
Abstract
Frontotemporal dementia (FTD) is a genetically and pathologically heterogeneous disorder characterized by personality changes, language impairment, and deficits of executive functions associated with frontal and temporal lobe degeneration. Different phenotypes have been defined on the basis of presenting clinical symptoms, i.e., the behavioral variant of FTD, the agrammatic variant of primary progressive aphasia, and the semantic variant of PPA. Some patients have an associated movement disorder, either parkinsonism, as in progressive supranuclear palsy and corticobasal syndrome, or motor neuron disease (FTD-MND). A family history of dementia is found in 40% of cases of FTD and about 10% have a clear autosomal-dominant inheritance. Genetic studies have identified several genes associated with monogenic FTD: microtubule-associated protein tau, progranulin, TAR DNA-binding protein 43, valosin-containing protein, charged multivesicular body protein 2B, fused in sarcoma, and the hexanucleotide repeat expansion in intron 1 of the chromosome 9 open reading frame 72. Patients often present with an extensive phenotypic variability, even among different members of the same kindred carrying an identical disease mutation. The objective of the present work is to review and evaluate available literature data in order to highlight recent advances in clinical, biological, and neuroimaging features of monogenic frontotemporal lobar degeneration and try to identify different mechanisms underlying the extreme phenotypic heterogeneity that characterizes this disease.
Collapse
Affiliation(s)
- Alberto Benussi
- Centre for Ageing Brain and Neurodegenerative Disorders, Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
| | - Alessandro Padovani
- Centre for Ageing Brain and Neurodegenerative Disorders, Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
| | - Barbara Borroni
- Centre for Ageing Brain and Neurodegenerative Disorders, Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
| |
Collapse
|
43
|
Rohrer JD, Nicholas JM, Cash DM, van Swieten J, Dopper E, Jiskoot L, van Minkelen R, Rombouts SA, Cardoso MJ, Clegg S, Espak M, Mead S, Thomas DL, De Vita E, Masellis M, Black SE, Freedman M, Keren R, MacIntosh BJ, Rogaeva E, Tang-Wai D, Tartaglia MC, Laforce R, Tagliavini F, Tiraboschi P, Redaelli V, Prioni S, Grisoli M, Borroni B, Padovani A, Galimberti D, Scarpini E, Arighi A, Fumagalli G, Rowe JB, Coyle-Gilchrist I, Graff C, Fallström M, Jelic V, Ståhlbom AK, Andersson C, Thonberg H, Lilius L, Frisoni GB, Pievani M, Bocchetta M, Benussi L, Ghidoni R, Finger E, Sorbi S, Nacmias B, Lombardi G, Polito C, Warren JD, Ourselin S, Fox NC, Rossor MN, Binetti G. Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. Lancet Neurol 2015; 14:253-62. [PMID: 25662776 PMCID: PMC6742501 DOI: 10.1016/s1474-4422(14)70324-2] [Citation(s) in RCA: 371] [Impact Index Per Article: 41.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
BACKGROUND Frontotemporal dementia is a highly heritable neurodegenerative disorder. In about a third of patients, the disease is caused by autosomal dominant genetic mutations usually in one of three genes: progranulin (GRN), microtubule-associated protein tau (MAPT), or chromosome 9 open reading frame 72 (C9orf72). Findings from studies of other genetic dementias have shown neuroimaging and cognitive changes before symptoms onset, and we aimed to identify whether such changes could be shown in frontotemporal dementia. METHODS We recruited participants to this multicentre study who either were known carriers of a pathogenic mutation in GRN, MAPT, or C9orf72, or were at risk of carrying a mutation because a first-degree relative was a known symptomatic carrier. We calculated time to expected onset as the difference between age at assessment and mean age at onset within the family. Participants underwent a standardised clinical assessment and neuropsychological battery. We did MRI and generated cortical and subcortical volumes using a parcellation of the volumetric T1-weighted scan. We used linear mixed-effects models to examine whether the association of neuropsychology and imaging measures with time to expected onset of symptoms differed between mutation carriers and non-carriers. FINDINGS Between Jan 30, 2012, and Sept 15, 2013, we recruited participants from 11 research sites in the UK, Italy, the Netherlands, Sweden, and Canada. We analysed data from 220 participants: 118 mutation carriers (40 symptomatic and 78 asymptomatic) and 102 non-carriers. For neuropsychology measures, we noted the earliest significant differences between mutation carriers and non-carriers 5 years before expected onset, when differences were significant for all measures except for tests of immediate recall and verbal fluency. We noted the largest Z score differences between carriers and non-carriers 5 years before expected onset in tests of naming (Boston Naming Test -0·7; SE 0·3) and executive function (Trail Making Test Part B, Digit Span backwards, and Digit Symbol Task, all -0·5, SE 0·2). For imaging measures, we noted differences earliest for the insula (at 10 years before expected symptom onset, mean volume as a percentage of total intracranial volume was 0·80% in mutation carriers and 0·84% in non-carriers; difference -0·04, SE 0·02) followed by the temporal lobe (at 10 years before expected symptom onset, mean volume as a percentage of total intracranial volume 8·1% in mutation carriers and 8·3% in non-carriers; difference -0·2, SE 0·1). INTERPRETATION Structural imaging and cognitive changes can be identified 5-10 years before expected onset of symptoms in asymptomatic adults at risk of genetic frontotemporal dementia. These findings could help to define biomarkers that can stage presymptomatic disease and track disease progression, which will be important for future therapeutic trials. FUNDING Centres of Excellence in Neurodegeneration.
Collapse
Affiliation(s)
| | - Jennifer M Nicholas
- Dementia Research Centre, University College London, London, UK; Department of Medical Statistics, London School of Hygiene & Tropical Medicine, London, UK
| | - David M Cash
- Dementia Research Centre, University College London, London, UK; Department of Neurodegenerative Disease, University College London Institute of Neurology, and Centre for Medical Image Computing, University College London, London, UK
| | - John van Swieten
- Department of Neurology, Erasmus Medical Center, Rotterdam, Netherlands
| | - Elise Dopper
- Department of Neurology, Erasmus Medical Center, Rotterdam, Netherlands
| | - Lize Jiskoot
- Department of Neurology, Erasmus Medical Center, Rotterdam, Netherlands
| | - Rick van Minkelen
- Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, Netherlands
| | - Serge A Rombouts
- Institute of Psychology, Leiden University, and Department of Radiology, Leiden University Medical Center, Leiden, Netherlands
| | - M Jorge Cardoso
- Dementia Research Centre, University College London, London, UK; Department of Neurodegenerative Disease, University College London Institute of Neurology, and Centre for Medical Image Computing, University College London, London, UK
| | - Shona Clegg
- Dementia Research Centre, University College London, London, UK
| | - Miklos Espak
- Dementia Research Centre, University College London, London, UK; Department of Neurodegenerative Disease, University College London Institute of Neurology, and Centre for Medical Image Computing, University College London, London, UK
| | - Simon Mead
- Medical Research Council Prion Unit, University College London, London, UK
| | - David L Thomas
- Dementia Research Centre, University College London, London, UK; Neuroradiological Academic Unit, Department of Brain Repair and Rehabilitation, University College London, London, UK
| | - Enrico De Vita
- Neuroradiological Academic Unit, Department of Brain Repair and Rehabilitation, University College London, London, UK; Lysholm Department of Neuroradiology, National Hospital for Neurology and Neurosurgery, London, UK
| | - Mario Masellis
- LC Campbell Cognitive Neurology Research Unit, Department of Medicine, Division of Neurology, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada
| | - Sandra E Black
- LC Campbell Cognitive Neurology Research Unit, Department of Medicine, Division of Neurology, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada
| | - Morris Freedman
- Department of Medicine, Division of Neurology, Baycrest, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada; Rotman Research Institute, Baycrest, Toronto, ON, Canada
| | - Ron Keren
- University Health Network Memory Clinic, Toronto Western Hospital, Toronto, ON, Canada
| | - Bradley J MacIntosh
- LC Campbell Cognitive Neurology Research Unit, Department of Medicine, Division of Neurology, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada
| | - Ekaterina Rogaeva
- Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada
| | - David Tang-Wai
- University Health Network Memory Clinic, Toronto Western Hospital, Toronto, ON, Canada
| | - Maria Carmela Tartaglia
- Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada
| | - Robert Laforce
- Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques, Hôpital de l'Enfant-Jésus, and Faculté de Médecine, Université Laval, QC, Canada
| | - Fabrizio Tagliavini
- Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta, Milano, Italy
| | - Pietro Tiraboschi
- Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta, Milano, Italy
| | - Veronica Redaelli
- Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta, Milano, Italy
| | - Sara Prioni
- Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta, Milano, Italy
| | - Marina Grisoli
- Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta, Milano, Italy
| | - Barbara Borroni
- Neurology Unit, Department of Medical and Experimental Sciences, University of Brescia, Brescia, Italy
| | - Alessandro Padovani
- Neurology Unit, Department of Medical and Experimental Sciences, University of Brescia, Brescia, Italy
| | - Daniela Galimberti
- Neurology Unit, Department of Physiopathology and Transplantation, University of Milan, Fondazione Cà Granda, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico, Milan, Italy
| | - Elio Scarpini
- Neurology Unit, Department of Physiopathology and Transplantation, University of Milan, Fondazione Cà Granda, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico, Milan, Italy
| | - Andrea Arighi
- Neurology Unit, Department of Physiopathology and Transplantation, University of Milan, Fondazione Cà Granda, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico, Milan, Italy
| | - Giorgio Fumagalli
- Neurology Unit, Department of Physiopathology and Transplantation, University of Milan, Fondazione Cà Granda, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico, Milan, Italy
| | - James B Rowe
- Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
| | - Ian Coyle-Gilchrist
- Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
| | - Caroline Graff
- Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Neurogeriatrics, Karolinska Institutet, Huddinge, Sweden; Department of Geriatric Medicine, Karolinska University Hospital-Huddinge, Stockholm, Sweden
| | - Marie Fallström
- Department of Geriatric Medicine, Karolinska University Hospital-Huddinge, Stockholm, Sweden
| | - Vesna Jelic
- Division of Clinical Geriatrics, Karolinska Institutet, Huddinge, Sweden; Department of Geriatric Medicine, Karolinska University Hospital-Huddinge, Stockholm, Sweden
| | - Anne Kinhult Ståhlbom
- Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Neurogeriatrics, Karolinska Institutet, Huddinge, Sweden; Department of Geriatric Medicine, Karolinska University Hospital-Huddinge, Stockholm, Sweden
| | - Christin Andersson
- Department of Clinical Neuroscience, Karolinska Institutet, Huddinge, Sweden; Department of Psychology, Karolinska University Hospital-Huddinge, Stockholm, Sweden
| | - Håkan Thonberg
- Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Neurogeriatrics, Karolinska Institutet, Huddinge, Sweden; Department of Geriatric Medicine, Karolinska University Hospital-Huddinge, Stockholm, Sweden
| | - Lena Lilius
- Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Neurogeriatrics, Karolinska Institutet, Huddinge, Sweden
| | - Giovanni B Frisoni
- Istituto di Ricovero e Cura a Carattere Scientifico Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy; Memory Clinic and LANVIE-Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Geneva, Switzerland
| | - Michela Pievani
- Istituto di Ricovero e Cura a Carattere Scientifico Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
| | - Martina Bocchetta
- Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy; Istituto di Ricovero e Cura a Carattere Scientifico Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
| | - Luisa Benussi
- Istituto di Ricovero e Cura a Carattere Scientifico Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
| | - Roberta Ghidoni
- Istituto di Ricovero e Cura a Carattere Scientifico Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
| | - Elizabeth Finger
- Department of Clinical Neurological Sciences, University of Western Ontario, London, ON, Canada
| | - Sandro Sorbi
- Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy
| | - Benedetta Nacmias
- Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy
| | - Gemma Lombardi
- Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy
| | - Cristina Polito
- Department of Clinical Pathophysiology, Nuclear Medicine Division, University of Florence, Florence, Italy
| | - Jason D Warren
- Dementia Research Centre, University College London, London, UK
| | - Sebastien Ourselin
- Dementia Research Centre, University College London, London, UK; Department of Neurodegenerative Disease, University College London Institute of Neurology, and Centre for Medical Image Computing, University College London, London, UK
| | - Nick C Fox
- Dementia Research Centre, University College London, London, UK
| | - Martin N Rossor
- Dementia Research Centre, University College London, London, UK.
| | | |
Collapse
|
44
|
A Voxel Based Morphometric Analysis of Longitudinal Cortical Gray Matter Changes in Progranulin Mutation Carriers At-Risk for Frontotemporal Dementia: Preliminary Study. Dement Neurocogn Disord 2015. [DOI: 10.12779/dnd.2015.14.4.163] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
|
45
|
Oishi K, Faria AV, Hsu J, Tippett D, Mori S, Hillis AE. Critical role of the right uncinate fasciculus in emotional empathy. Ann Neurol 2014; 77:68-74. [PMID: 25377694 DOI: 10.1002/ana.24300] [Citation(s) in RCA: 93] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2014] [Revised: 10/14/2014] [Accepted: 10/31/2014] [Indexed: 01/25/2023]
Abstract
OBJECTIVE Common neurological diseases or injuries that can affect the right hemisphere, including stroke, traumatic brain injury, and frontotemporal dementia, disrupt emotional empathy-the ability to share in and make inferences about how other people feel. This impairment negatively impacts social interactions and relationships. Accumulating evidence indicates that emotional empathy depends on coordinated functions of orbitofrontal cortex, anterior insula, anterior cingulate, temporal pole, and amygdala, but few studies have investigated effects of lesions to white matter tracts that connect these structures. We tested the hypothesis that percentage damage to specific white matter tracts connecting these gray matter structures predicts error rate in an emotional empathy task after acute right hemisphere ischemic stroke. METHODS We used multivariate linear regression with percentage damage to 8 white matter tracts, age, and education as independent variables and error rate on emotional empathy as the dependent variable to test a predictive model of emotional empathy in 30 patients with acute ischemic right hemisphere stroke. RESULTS Percentage damage to 8 white matter tracts along with age and education predicted the error rate in emotional empathy, but only percentage damage to the uncinate fasciculus was independently associated with error rate. Participants with right uncinate fasciculus lesions were significantly more impaired than right hemisphere stroke patients without uncinate fasciculus lesions in the emotional empathy task. INTERPRETATION The right uncinate fasciculus plays an important role in the emotional empathy network. Patients with lesions in this network should be evaluated for empathy, so that deficits can be addressed.
Collapse
|
46
|
|
47
|
Premi E, Cauda F, Gasparotti R, Diano M, Archetti S, Padovani A, Borroni B. Multimodal FMRI resting-state functional connectivity in granulin mutations: the case of fronto-parietal dementia. PLoS One 2014; 9:e106500. [PMID: 25188321 PMCID: PMC4154688 DOI: 10.1371/journal.pone.0106500] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2014] [Accepted: 08/07/2014] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Monogenic dementias represent a great opportunity to trace disease progression from preclinical to symptomatic stages. Frontotemporal Dementia related to Granulin (GRN) mutations presents a specific framework of brain damage, involving fronto-temporal regions and long inter-hemispheric white matter bundles. Multimodal resting-state functional MRI (rs-fMRI) is a promising tool to carefully describe disease signature from the earliest disease phase. OBJECTIVE To define local connectivity alterations in GRN related pathology moving from the presymptomatic (asymptomatic GRN mutation carriers) to the clinical phase of the disease (GRN- related Frontotemporal Dementia). METHODS Thirty-one GRN Thr272fs mutation carriers (14 patients with Frontotemporal Dementia and 17 asymptomatic carriers) and 38 healthy controls were recruited. Local connectivity measures (Regional Homogeneity (ReHo), Fractional Amplitude of Low Frequency Fluctuation (fALFF) and Degree Centrality (DC)) were computed, considering age and gender as nuisance variables as well as the influence of voxel-level gray matter atrophy. RESULTS Asymptomatic GRN carriers had selective reduced ReHo in the left parietal region and increased ReHo in frontal regions compared to healthy controls. Considering Frontotemporal Dementia patients, all measures (ReHo, fALFF and DC) were reduced in inferior parietal, frontal lobes and posterior cingulate cortex. Considering GRN mutation carriers, an inverse correlation with age in the posterior cingulate cortex, inferior parietal lobule and orbitofrontal cortex was found. CONCLUSIONS GRN pathology is characterized by functional brain network alterations even decades before the clinical onset; they involve the parietal region primarily and then spread to the anterior regions of the brain, supporting the concept of molecular nexopathies.
Collapse
Affiliation(s)
- Enrico Premi
- Centre for Ageing Brain and Neurodegenerative Disorders, Neurology Unit, University of Brescia, Brescia, Italy
| | - Franco Cauda
- Clinical and Experimental Center for Functional Magnetic Resonance Imaging, Koelliker Hospital, Turin, Italy
- Department of Psychology, University of Turin, Turin, Italy
| | | | - Matteo Diano
- Clinical and Experimental Center for Functional Magnetic Resonance Imaging, Koelliker Hospital, Turin, Italy
- Department of Psychology, University of Turin, Turin, Italy
| | | | - Alessandro Padovani
- Centre for Ageing Brain and Neurodegenerative Disorders, Neurology Unit, University of Brescia, Brescia, Italy
| | - Barbara Borroni
- Centre for Ageing Brain and Neurodegenerative Disorders, Neurology Unit, University of Brescia, Brescia, Italy
- * E-mail:
| |
Collapse
|
48
|
Abstract
Mutations in the progranulin gene (GRN) are a common cause of familial frontotemporal dementia. We used a comprehensive neuropsychological battery to investigate whether early cognitive changes could be detected in GRN mutation carriers before dementia onset. Twenty-four at-risk members from six families with known GRN mutations underwent detailed neuropsychological testing. Group differences were investigated by domains of attention, language, visuospatial function, verbal memory, non-verbal memory, working memory and executive function. There was a trend for mutation carriers (n=8) to perform more poorly than non-carriers (n=16) across neuropsychological domains, with significant between group differences for visuospatial function (p<.04; d=0.92) and working memory function (p<.02; d=1.10). Measurable cognitive differences exist before the development of frontotemporal dementia in subjects with GRN mutations. The neuropsychological profile of mutation carriers suggests early asymmetric, right hemisphere brain dysfunction that is consistent with recent functional imaging data from our research group and the broader literature.
Collapse
|
49
|
Caso F, Agosta F, Magnani G, Galantucci S, Spinelli EG, Galimberti D, Falini A, Comi G, Filippi M. Clinical and MRI correlates of disease progression in a case of nonfluent/agrammatic variant of primary progressive aphasia due to progranulin (GRN) Cys157LysfsX97 mutation. J Neurol Sci 2014; 342:167-72. [DOI: 10.1016/j.jns.2014.03.058] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2013] [Revised: 02/21/2014] [Accepted: 03/31/2014] [Indexed: 12/13/2022]
|
50
|
Premi E, Garibotto V, Gazzina S, Formenti A, Archetti S, Gasparotti R, Padovani A, Borroni B. Subcortical and Deep Cortical Atrophy in Frontotemporal Dementia due to Granulin Mutations. Dement Geriatr Cogn Dis Extra 2014; 4:95-102. [PMID: 24926307 PMCID: PMC4036148 DOI: 10.1159/000355428] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND/AIMS Parkinsonism is often associated with symptoms of frontotemporal dementia (FTD), but its pathogenesis has been largely neglected. In genetic inherited FTD-related granulin (GRN) mutations, parkinsonism is an early sign, and it is more common than in sporadic disorders. Our aim was to study grey matter (GM) volume changes in subcortical and deep cortical regions in GRN-related FTD. METHODS A total of 33 FTD patients (13 carriers of the GRN mutation, GRN+, and 20 non-carriers, GRN-) and 12 healthy controls (HC) were included in the study. Each subject underwent an MRI examination (1) for voxel-based morphometry to study GM differences in cortical and subcortical regions, and (2) for a region of interest approach using a probabilistic atlas of subcortical regions (caudate nucleus, putamen, thalamus and amygdala) to assess the regional differences. RESULTS The GRN+ group showed greater damage in frontotemporal regions than the GRN- group. The FTD patients had greater GM atrophy in the caudate nucleus and in the thalamus bilaterally than the HC. Damage to these subcortical and deep cortical regions was greater in the GRN+ than in the GRN- patients. DISCUSSION Subcortical and deep cortical involvement is a key feature of FTD, and more pronounced in GRN-related disease. Damage to the caudate region in GRN+ patients may explain the parkinsonism frequently associated since the early stages of the disease.
Collapse
Affiliation(s)
- Enrico Premi
- Centre for Ageing Brain and Neurodegenerative Disorders, Neurology Unit, Brescia, Italy
| | - Valentina Garibotto
- Department of Medical Imaging, Geneva University Hospital, Geneva, Switzerland
| | - Stefano Gazzina
- Centre for Ageing Brain and Neurodegenerative Disorders, Neurology Unit, Brescia, Italy
| | - Anna Formenti
- Centre for Ageing Brain and Neurodegenerative Disorders, Neurology Unit, Brescia, Italy
| | | | | | - Alessandro Padovani
- Centre for Ageing Brain and Neurodegenerative Disorders, Neurology Unit, Brescia, Italy
| | - Barbara Borroni
- Centre for Ageing Brain and Neurodegenerative Disorders, Neurology Unit, Brescia, Italy
| |
Collapse
|